Sanara MedTech (SMTI) 10-Q 12 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - $ / shares	9 Months Ended
	Sep. 30, 2024	Nov. 08, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-39678
Entity Registrant Name	SANARA MEDTECH INC.
Entity Central Index Key	0000714256
Entity Tax Identification Number	59-2219994
Entity Incorporation, State or Country Code	TX
Entity Address, Address Line One	1200 Summit Ave
Entity Address, Address Line Two	Suite 414
Entity Address, City or Town	Fort Worth
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	76102
City Area Code	(817)
Local Phone Number	529-2300
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	SMTI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,741,161
Entity Listing, Par Value Per Share	$ 0.001

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2024		Dec. 31, 2023
Current assets
Cash	$ 16,277,189		$ 5,147,216
Royalty receivable			49,344
Inventory, net	3,008,349		4,717,533
Convertible loan receivable	1,079,411
Prepaid and other assets	429,428		608,411
Total current assets	31,908,408		19,005,869
Long-term assets
Intangible assets, net	42,029,142		44,926,061
Goodwill	3,601,781		3,601,781
Investment in equity securities	8,321,412		3,084,278
Right of use assets – operating leases	1,688,963		1,995,204
Property and equipment, net	995,770		1,257,956
Total long-term assets	56,637,068		54,865,280
Total assets	88,545,476	[1]	73,871,149
Current liabilities
Accrued bonuses and commissions	8,256,801		7,676,770
Accrued royalties and expenses	2,285,374		2,047,678
Earnout liabilities – current	1,906,550		1,100,000
Current portion of debt			580,357
Operating lease liabilities – current	439,129		361,185
Total current liabilities	14,339,827		13,767,877
Long-term liabilities
Long-term debt, net of current portion	30,076,715		9,113,123
Earnout liabilities – long-term	2,006,000		2,723,001
Operating lease liabilities – long-term	1,407,164		1,737,445
Other long-term liabilities	1,261,495		1,941,686
Total long-term liabilities	34,751,374		15,515,255
Total liabilities	49,091,201		29,283,132
Commitments and contingencies (Note 9)
Shareholders’ equity
Common Stock: $0.001 par value, 20,000,000 shares authorized; 8,743,174 issued and outstanding as of September 30, 2024 and 8,535,239 issued and outstanding as of December 31, 2023	8,743		8,535
Additional paid-in capital	76,021,528		72,860,556
Accumulated deficit	(36,246,405)		(28,036,814)
Total Sanara MedTech shareholders’ equity	39,783,866		44,832,277
Equity attributable to noncontrolling interest	(329,591)		(244,260)
Total shareholders’ equity	39,454,275		44,588,017
Total liabilities and shareholders’ equity	88,545,476		73,871,149
Nonrelated Party [Member]
Current assets
Accounts receivable	11,070,622		8,474,965
Current liabilities
Accounts payable	1,301,362		1,924,082
Related Party [Member]
Current assets
Accounts receivable	43,409		8,400
Current liabilities
Accounts payable	$ 150,611		$ 77,805
[1]- Segment assets for 2023 represent assets as of December 31, 2023.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	20,000,000	20,000,000
Common stock, shares issued	8,743,174	8,535,239
Common stock, shares outstanding	8,743,174	8,535,239

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Net Revenue	$ 21,671,599	$ 16,024,948	$ 60,367,060	$ 47,300,029
Cost of goods sold	1,991,987	1,751,349	5,890,719	6,064,524
Gross profit	19,679,612	14,273,599	54,476,341	41,235,505
Operating expenses
Selling, general and administrative expenses	18,993,255	13,877,879	54,143,122	40,658,424
Research and development	1,359,530	986,454	3,291,479	3,480,906
Depreciation and amortization	1,103,854	997,674	3,314,781	2,580,243
Change in fair value of earnout liabilities	147,000	(681,753)	67,549	(1,494,910)
Total operating expenses	21,603,639	15,180,254	60,816,931	45,224,663
Operating loss	(1,924,027)	(906,655)	(6,340,590)	(3,989,158)
Other expense
Interest expense	(927,577)	(188,294)	(1,839,259)	(188,300)
Share of losses from equity method investment	(31,448)		(31,448)
Total other expense	(959,025)	(188,294)	(1,870,707)	(188,300)
Net loss	(2,883,052)	(1,094,949)	(8,211,297)	(4,177,458)
Less: Net loss attributable to noncontrolling interest	(25,284)	(34,579)	(85,331)	(111,455)
Net loss attributable to Sanara MedTech shareholders	$ (2,857,768)	$ (1,060,370)	$ (8,125,966)	$ (4,066,003)
Net loss per share of common stock, basic	$ (0.34)	$ (0.13)	$ (0.96)	$ (0.49)
Net loss per share of common stock, diluted	$ (0.34)	$ (0.13)	$ (0.96)	$ (0.49)
Weighted average number of common shares outstanding, basic	8,517,381	8,332,341	8,468,394	8,244,503
Weighted average number of common shares outstanding, diluted	8,517,381	8,332,341	8,468,394	8,244,503

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2022	$ 8,300	$ 65,213,987	$ (23,394,757)	$ (107,555)	$ 41,719,975
Balance, shares at Dec. 31, 2022	8,299,957
Share-based compensation	$ 75	597,230			597,305
Share-based compensation, shares	74,781
Net settlement and retirement of equity-based awards	$ (16)	(315,572)	(340,354)		(655,942)
Net settlement and retirement of equity-based awards, shares	(15,854)
Issuance of common stock in equity offering	$ 26	1,033,735			1,033,761
Issuance of common stock in equity offering, shares	26,143
Net loss			(1,177,900)	(38,429)	(1,216,329)
Balance at Mar. 31, 2023	$ 8,385	66,529,380	(24,913,011)	(145,984)	41,478,770
Balance, shares at Mar. 31, 2023	8,385,027
Balance at Dec. 31, 2022	$ 8,300	65,213,987	(23,394,757)	(107,555)	41,719,975
Balance, shares at Dec. 31, 2022	8,299,957
Net loss					(4,177,458)
Balance at Sep. 30, 2023	$ 8,540	72,107,881	(27,799,621)	(219,010)	44,097,790
Balance, shares at Sep. 30, 2023	8,540,226
Balance at Dec. 31, 2022	$ 8,300	65,213,987	(23,394,757)	(107,555)	41,719,975
Balance, shares at Dec. 31, 2022	8,299,957
Balance at Dec. 31, 2023	$ 8,535	72,860,556	(28,036,814)	(244,260)	44,588,017
Balance, shares at Dec. 31, 2023	8,535,239
Balance at Mar. 31, 2023	$ 8,385	66,529,380	(24,913,011)	(145,984)	41,478,770
Balance, shares at Mar. 31, 2023	8,385,027
Share-based compensation	$ 33	1,127,299			1,127,332
Share-based compensation, shares	33,355
Net settlement and retirement of equity-based awards	$ 22	224,740	(186)		224,576
Net settlement and retirement of equity-based awards, shares	21,363
Net loss			(1,827,733)	(38,447)	(1,866,180)
Balance at Jun. 30, 2023	$ 8,440	67,881,419	(26,740,930)	(184,431)	40,964,498
Balance, shares at Jun. 30, 2023	8,439,745
Share-based compensation	$ (1)	857,527			857,526
Share-based compensation, shares	(339)
Net settlement and retirement of equity-based awards	$ 27	279,364	1,679		281,070
Net settlement and retirement of equity-based awards, shares	27,011
Net loss			(1,060,370)	(34,579)	(1,094,949)
Issuance of common stock for acquisitions	$ 74	3,089,571			3,089,645
Issuance of common stock for acquisitions, shares	73,809
Balance at Sep. 30, 2023	$ 8,540	72,107,881	(27,799,621)	(219,010)	44,097,790
Balance, shares at Sep. 30, 2023	8,540,226
Balance at Dec. 31, 2023	$ 8,535	72,860,556	(28,036,814)	(244,260)	44,588,017
Balance, shares at Dec. 31, 2023	8,535,239
Share-based compensation	$ 101	803,285			803,386
Share-based compensation, shares	100,662
Net settlement and retirement of equity-based awards	$ (13)	(483,633)	(97,148)		(580,794)
Net settlement and retirement of equity-based awards, shares	(13,162)
Net loss			(1,764,184)	(34,859)	(1,799,043)
Balance at Mar. 31, 2024	$ 8,623	73,180,208	(29,898,146)	(279,119)	43,011,566
Balance, shares at Mar. 31, 2024	8,622,739
Balance at Dec. 31, 2023	$ 8,535	72,860,556	(28,036,814)	(244,260)	44,588,017
Balance, shares at Dec. 31, 2023	8,535,239
Net loss					(8,211,297)
Balance at Sep. 30, 2024	$ 8,743	76,021,528	(36,246,405)	(329,591)	39,454,275
Balance, shares at Sep. 30, 2024	8,743,174
Balance at Mar. 31, 2024	$ 8,623	73,180,208	(29,898,146)	(279,119)	43,011,566
Balance, shares at Mar. 31, 2024	8,622,739
Share-based compensation	$ 67	1,411,478			1,411,545
Share-based compensation, shares	67,294
Net settlement and retirement of equity-based awards	$ 57	493,829	14,200		508,086
Net settlement and retirement of equity-based awards, shares	56,943
Net loss			(3,504,014)	(25,188)	(3,529,202)
Balance at Jun. 30, 2024	$ 8,747	75,085,515	(33,387,960)	(304,307)	41,401,995
Balance, shares at Jun. 30, 2024	8,746,976
Share-based compensation	$ (3)	1,025,434			1,025,431
Share-based compensation, shares	(3,368)
Net settlement and retirement of equity-based awards		(14,421)	(677)		(15,099)
Net settlement and retirement of equity-based awards, shares	(434)
Issuance of common stock in equity offering		(75,000)			(75,000)
Net loss			(2,857,768)	(25,284)	(2,883,052)
Balance at Sep. 30, 2024	$ 8,743	$ 76,021,528	$ (36,246,405)	$ (329,591)	$ 39,454,275
Balance, shares at Sep. 30, 2024	8,743,174

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (8,211,297)	$ (4,177,458)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,314,781	2,580,243
Credit loss expense	230,930	214,061
Inventory obsolescence	356,261	222,691
Share-based compensation	3,240,362	2,582,163
Noncash lease expense	306,240	243,988
Share of losses from equity method investment	31,448
Back-end fee	219,689
Paid-in-kind interest	424,067
Accretion of finance liabilities	166,595	39,699
Amortization and write-off of debt issuance costs	150,219	2,055
Change in fair value of earnout liabilities	67,549	(1,494,910)
Changes in operating assets and liabilities:
Accounts receivable, net	(2,777,243)	(794,344)
Accounts receivable – related parties	(35,009)	87,516
Inventory, net	1,352,923	(1,664,714)
Prepaid and other assets	178,963	482,921
Accounts payable	(622,719)	547,186
Accounts payable – related parties	72,806	30,711
Accrued royalties and expenses	249,910	557,295
Accrued bonuses and commissions	580,031	(1,673,629)
Operating lease liabilities	(252,337)	(182,498)
Net cash used in operating activities	(955,831)	(2,397,024)
Cash flows from investing activities:
Purchases of property and equipment	(133,676)	(210,970)
Proceeds from disposal of property and equipment		650
Investment in equity securities	(5,268,582)
Advancement on convertible loan receivable	(1,079,391)
Acquisitions, net of cash acquired		(9,942,750)
Net cash used in investing activities	(6,481,649)	(10,153,070)
Cash flows from financing activities:
Loan proceeds, net	29,339,260	9,688,341
Pay off line of credit	(9,750,000)
Equity offering net proceeds (expenses)	(75,000)	1,033,761
Net settlement of equity-based awards	(87,807)	(150,296)
Cash payment of finance and earnout liabilities	(859,000)	(744,795)
Net cash provided by financing activities	18,567,453	9,827,011
Net increase (decrease) in cash	11,129,973	(2,723,083)
Cash, beginning of period	5,147,216	8,958,995
Cash, end of period	16,277,189	6,235,912
Cash paid during the period for:
Interest	948,759	146,546
Supplemental noncash investing and financing activities:
Right of use assets obtained in exchange for lease obligations		1,531,773
Equity issued for acquisitions		3,089,645
Earnout and other liabilities generated by acquisitions		$ 3,759,642

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (2,857,768)	$ (1,060,370)	$ (8,125,966)	$ (4,066,003)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10b5-1 Arrangement Modified	false
Non-Rule 10b5-1 Arrangement Modified	false

NATURE OF BUSINESS AND BACKGROU

NATURE OF BUSINESS AND BACKGROUND	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF BUSINESS AND BACKGROUND	NOTE 1 – NATURE OF BUSINESS AND BACKGROUND Sanara MedTech Inc. (together with its wholly owned and majority owned subsidiaries on a consolidated basis, the “Company”) is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Each of the Company’s products, services and technologies are designed to achieve the Company’s goal of providing better clinical outcomes at a lower overall cost for patients, regardless of where they receive care. The Company strives to be one of the most innovative and comprehensive providers of effective surgical, wound and skincare solutions and is continually seeking to expand its offerings for patients requiring treatments across the entire continuum of care in the United States. In June 2020, the Company formed a subsidiary, United Wound and Skin Solutions, LLC (formerly known as “WounDerm”), to hold certain investments and operations in wound and skincare virtual consult services. In 2023, WounDerm was renamed to, and is now doing business as, “Tissue Health Plus” (“THP”). THP is continuing its mission to simplify skin health, starting with wound care through a refined business plan. Through THP, the Company plans to offer a first of its kind value-based wound care program to payers and risk-bearing entities such as accountable care organizations and value-based care (“VBC”) primary care companies, with Medicare Advantage payers as the initial target market for this program. As further discussed in Note 12, the Company historically managed its business on the basis of one two Sanara Surgical The Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Sanara Surgical’s soft tissue repair products include, among other products, the Company’s lead product, CellerateRX Surgical Activated Collagen (“CellerateRX Surgical”), and BIASURGE Advanced Surgical Solution, which is a no-rinse, advanced surgical solution used for wound irrigation. Sanara Surgical’s bone fusion products include, among other products, BiFORM, which is an osteoconductive, bioactive, porous implant that allows for bony ingrowth across the graft site, and ALLOCYTE Plus, which is a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers. Sanara Surgical also includes an in-house research and development team (Rochal Technologies) with an extensive pipeline of innovative products under development. Tissue Health Plus The THP segment is focused on value-based wound care services. Through THP, the Company plans to offer a first of its kind value-based wound care program to payers and risk-bearing entities such as accountable care organizations and VBC primary care companies, with Medicare Advantage payers as the initial target market for this program. THP’s programs are expected to enable payers to divest wound care spend risk, reduce wound related hospitalizations and improve patient quality of life. THP plans to coordinate delivery of community and home-based wound care for its managed patients. Community-based care spans a variety of settings including physician offices, skilled nursing facilities, assisted living facilities and senior living facilities. THP’s programs are intended to integrate science and evidence-based medicine protocols to standardize wound prevention and treatment. As a result of the change in reportable segments, certain prior period amounts have been recast to conform to the current period presentation. Throughout this Quarterly Report on Form 10-Q, unless otherwise indicated, amounts and activity reflect reclassifications related to the Company’s change in reportable segments. The change in reportable segments had no impact on the Company’s previously reported Consolidated Balance Sheets, Consolidated Statements of Operations, Consolidated Statements of Cash Flows or Consolidated Statements of Shareholders’ Equity.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation and Basis of Presentation The accompanying unaudited consolidated financial statements include the accounts of Sanara MedTech Inc. and its wholly owned and majority-owned subsidiaries, as well as other entities in which the Company has a controlling financial interest. All significant intercompany profits, losses, transactions and balances have been eliminated in consolidation. Certain prior year amounts have been reclassified to conform to the current year presentation. The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management of the Company, all adjustments (consisting of normal accruals) considered necessary for a fair presentation have been included. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full year period. These financial statements and notes should be read in conjunction with the financial statements for each of the two years ended December 31, 2023 and 2022, which are included in the Company’s most recent Annual Report on Form 10-K. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported revenue and expenses during the reporting period. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Income/Loss Per Share The Company computes income/loss per share in accordance with Accounting Standards Codification (“ASC”) Topic 260, Earnings per Share, which requires the Company to present basic and diluted income per share when the effect is dilutive. Basic income/loss per share is computed by dividing income/loss attributable to common shareholders by the weighted average number of shares of common stock outstanding. Diluted income/loss per share is computed similarly to basic income/loss per share, except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. All common stock equivalents were excluded from the calculations for the periods presented as their inclusion would have been anti-dilutive during the three and nine months ended September 30, 2024 and 2023 due to the Company’s net loss. The following table summarizes the shares of common stock that were potentially issuable but were excluded from the computation of diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 as such shares would have had an anti-dilutive effect: SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE 2024 2023 As of September 30, 2024 2023 Stock options (a) 31,013 95,873 Warrants (b) 16,725 16,725 Unvested restricted stock 224,392 159,557 Anti-dilutive securities 224,392 159,557 (a) Shares underlying stock options assumed pursuant to the merger agreement with Precision Healing, Inc. (“Precision Healing”) in April 2022. (b) Shares underlying warrants assumed pursuant to the merger agreement with Precision Healing in April 2022. Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when a purchase order is received from the customer and control of the promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for transferring those goods or services. Revenue is recognized based on the following five-step model: - Identification of the contract with a customer - Identification of the performance obligations in the contract - Determination of the transaction price - Allocation of the transaction price to the performance obligations in the contract - Recognition of revenue when, or as, the Company satisfies a performance obligation Details of this five-step process are as follows: Identification of the contract with a customer Customer purchase orders are generally considered to be contracts under ASC 606. Purchase orders typically identify the specific terms of products to be delivered, create the enforceable rights and obligations of both parties and result in commercial substance. No other forms of contract revenue recognition, such as the completed contract or percentage of completion methods, were utilized by the Company in either 2024 or 2023. Performance obligations The Company’s performance obligation is generally limited to delivery of the requested items to its customers at the agreed upon quantities and prices. Determination and allocation of the transaction price The Company has established prices for its products. These prices are effectively agreed to when customers place purchase orders with the Company. Rebates and discounts, if any, are recognized in full at the time of sale as a reduction of net revenue. Allocation of transaction prices is not necessary where only one performance obligation exists. Recognition of revenue as performance obligations are satisfied Product revenues are recognized when a purchase order is received from the customer, the products are delivered, and control of the goods and services passes to the customer. Disaggregation of Revenue Revenue streams from product sales and royalties are summarized below for the three and nine months ended September 30, 2024 and 2023. SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES 2024 2023 2024 2023 Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Soft tissue repair products $ 18,863,335 $ 13,634,316 $ 52,586,945 $ 39,756,539 Bone fusion products 2,808,264 2,340,382 7,779,209 7,392,740 Royalty revenue - 50,250 906 150,750 Total Net Revenue $ 21,671,599 $ 16,024,948 $ 60,367,060 $ 47,300,029 For the three and nine months ended September 30, 2024 and 2023, all of the Company’s net revenue was generated from Sanara Surgical. The Company plans to commercially launch the THP program in mid-2025. Accounts Receivable Allowances Accounts receivable are typically due within 30 days of invoicing. The Company establishes an allowance for credit losses to provide for an estimate of accounts receivable which are not expected to be collectible. The Company bases the allowance on an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and other information as applicable and will record its allowance based on the estimated credit losses. The Company recorded credit loss expense of $ 75,000 128,061 230,930 214,061 758,960 528,030 5,010 3,820 Inventories Inventories are stated at the lower of cost or net realizable value, with cost computed on a first-in, first-out basis. Inventories consist primarily of finished goods, and also include an immaterial amount of raw materials and related packaging components. The Company recorded inventory obsolescence expense of $ 96,684 152,701 356,261 222,691 466,276 446,917 Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the related assets, ranging from two ten years SCHEDULE OF PROPERTY AND EQUIPMENT Useful September 30, December 31, Life 2024 2023 Computers 3 5 $ 235,388 $ 194,788 Office equipment 3 7 216,491 201,785 Furniture and fixtures 5 10 346,508 304,338 Leasehold improvements 2 5 170,370 134,170 Internal use software 5 1,618,999 1,618,999 Property and equipment, gross 2,587,756 2,454,080 Less accumulated depreciation (1,591,986 ) (1,196,124 ) Property and equipment, net $ 995,770 $ 1,257,956 Depreciation expense related to property and equipment was $ 129,592 116,596 395,862 332,762 Internal Use Software The Company accounts for costs incurred to develop or acquire computer software for internal use in accordance with ASC Topic 350-40, Intangibles – Goodwill and Other. The Company capitalizes the costs incurred during the application development stage, which generally includes third-party developer fees to design the software configuration and interfaces, coding, installation and testing. The Company begins capitalization of qualifying costs when both the preliminary project stage is completed and management has authorized further funding for the completion of the project. Costs incurred during the preliminary project stage along with post implementation stages of internal-use computer software are expensed as incurred. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized development costs are classified as “Property and equipment, net” in the Consolidated Balance Sheets and are depreciated over the estimated useful life of the software, which is generally five years Goodwill The excess of purchase price over the fair value of identifiable net assets acquired in business combinations is recorded as goodwill. As of September 30, 2024 and December 31, 2023, all of the Company’s goodwill relates to the acquisition of Scendia Biologics, LLC (“Scendia”), which is included in the Sanara Surgical segment. Goodwill has an indefinite useful life and is not amortized. Goodwill is tested annually as of December 31 for impairment, or more frequently if circumstances indicate impairment may have occurred. The Company may first perform a qualitative assessment to determine if it is more likely than not that the fair value of the reporting unit is less than the respective carrying value. If it is determined that it is more likely than not that a reporting unit’s fair value is less than its carrying value, then the Company will determine the fair value of the reporting unit and record an impairment charge for the difference between fair value and carrying value (not to exceed the carrying amount of goodwill). No Intangible Assets Intangible assets are stated at cost of acquisition less accumulated amortization and impairment loss, if any. Cost of acquisition includes the purchase price and any cost directly attributable to bringing the asset to its working condition for the intended use. The Company amortizes its finite-lived intangible assets on a straight-line basis over the estimated useful life of the respective assets which is generally the life of the related patents or licenses, seven years for customer relationships and five years for assembled workforces. See Note 5 for more information on intangible assets. Impairment of Long-Lived Assets Long-lived assets, including certain identifiable intangibles held and to be used by the Company, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows and the estimated liquidation value of such long-lived assets and provides for impairment if such undiscounted cash flows are insufficient to recover the carrying amount of the long-lived assets. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value. Fair values are determined based on quoted market values, undiscounted cash flows or internal and external appraisals, as applicable. Assets to be disposed of are carried at the lower of carrying value or estimated fair value less cost to sell. No Investments in Equity Securities The Company’s equity investments consist of nonmarketable equity securities in privately held companies without readily determinable fair values. Unless accounted for under the equity method of accounting, the investments are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment in the same issuer. The Company applies the equity method of accounting to investments when it has significant influence, but not controlling interest, in the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. As discussed further in Note 6 as of September 30, 2024, the Company had one investment that is recorded applying the equity method of accounting. The Company’s proportionate share of the net income (loss) resulting from these investments is reported under the line item captioned “Share of losses from equity method investment” in the Company’s Consolidated Statements of Operations. The Company’s equity method investment is adjusted each period for the Company’s share of the investee’s income or loss and dividend paid, if any. The Company classifies distributions received from its equity method investment using the cumulative earnings approach in the Company’s Consolidated Statements of Cash Flows. The Company has reviewed the carrying value of its investments and has determined there was no impairment or observable price changes as of or for the three and nine months ended September 30, 2024 and 2023. Fair Value Measurement As defined in ASC Topic 820, Fair Value Measurement (“ASC 820”), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). This fair value measurement framework applies at both the initial and subsequent measurement. The three levels of the fair value hierarchy defined by ASC 820 are as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities. Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include nonexchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars. Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value. The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses, other than acquisition-related expenses, approximate fair value because of the short-term nature of these instruments. The fair value of acquisition-related accrued expenses is categorized as Level 2 of the fair value hierarchy. The value of these instruments has been estimated using discounted cash flow analysis based on the Company’s incremental borrowing rate. The carrying value of the Company’s CRG Term Loan (defined below), which has a fixed interest rate approximates fair value based on instruments with similar terms (Level 2 inputs). The carrying value of the Company’s Cadence Term Loan (defined below), which had variable interest rates determined each month, approximates fair value based on instruments with similar terms (Level 2 inputs). The fair value of the contingent earnout consideration and the acquisition date fair value of goodwill and intangibles related to the acquisitions discussed in Notes 3 and 5 are based on Level 3 inputs. Liabilities for contingent consideration for the Precision Healing merger, acquisition of Scendia and Applied Asset Purchase (defined below) (see Note 3 for more information) are measured at fair value each reporting period, with the acquisition-date fair value included as part of the consideration transferred. The contingent consideration for the Scendia acquisition was settled as of September 30, 2024, and the final earnout payment of approximately $1.1 million was paid in cash in October 2024. Subsequent changes in fair value for the Precision Healing merger are reported under the line item captioned “Change in fair value of earnout liabilities” in the Company’s Consolidated Statements of Operations. Due to the Applied Asset Purchase being accounted for as an asset acquisition and given that the transaction did not include contingent shares, subsequent revaluations of contingent consideration for the Applied Asset Purchase results in an adjustment to the contingent consideration liability and the intellectual property intangible asset with a cumulative catch-up amortization adjustment. The current year change in fair value of earnout liability below is as a result of a net increase in the estimated fair value of the earnout liability established at the time of the Company’s Precision Healing merger. The current year revaluation of earnout liability below is a result of an increase in the estimated value of the earnout liability established at the time of the Applied Asset Purchase. The following table sets forth a summary of the changes in fair value for the Level 3 contingent earnout considerations. SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION Balance at December 31, 2023 $ 3,823,001 Change in fair value of earnout liabilities 67,549 Revaluation of earnout liability 22,000 Balance at September 30, 2024 $ 3,912,550 Income Taxes Income taxes are accounted for under the asset and liability method, whereby deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all the deferred tax asset will not be realized. Share-based Compensation The Company accounts for share-based compensation to employees and nonemployees in accordance with ASC Topic 718, Compensation – Stock Compensation. Share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as expense over the stipulated vesting period, if any. The Company estimates the fair value of share-based payments using the Black-Scholes option-pricing model for common stock options and warrants, and the closing price of the Company’s common stock for grants of common stock, including restricted stock awards. Research and Development Costs Research and development (“R&D”) expenses consist of personnel-related expenses, including salaries, share-based compensation and benefits for all personnel directly engaged in R&D activities, contracted services, materials, prototype expenses and allocated overhead, which is comprised of compensation and benefits, lease expense and other facilities-related costs. R&D expenses include costs related to enhancements to the Company’s currently available products and additional investments in the product and platform development pipeline. The Company expenses R&D costs as incurred. Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326). This update amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The Company adopted the new guidance effective January 1, 2023. The adoption did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows. Recently Issued Accounting Pronouncements In November 2023, FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires disclosure of incremental segment information on an annual and interim basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company is currently evaluating the effect of this pronouncement on its disclosures. In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which expands the disclosure required for income taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.

APPLIED ASSET PURCHASE

APPLIED ASSET PURCHASE	9 Months Ended
	Sep. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
APPLIED ASSET PURCHASE	NOTE 3 – APPLIED ASSET PURCHASE On August 1, 2023, the Company entered into an Asset Purchase Agreement (the “Applied Purchase Agreement”) by and among the Company, as guarantor, Sanara MedTech Applied Technologies, LLC, a Texas limited liability company and wholly owned subsidiary of the Company (“SMAT”), The Hymed Group Corporation, a Delaware corporation (“Hymed”), Applied Nutritionals, LLC, a Delaware limited liability company (“Applied”, and together with Hymed, the “Sellers”), and Dr. George D. Petito (the “Owner”), pursuant to which SMAT acquired certain assets of the Sellers and the Owner, including, among others, the Sellers’ and Owner’s inventory, intellectual property, manufacturing and related equipment, goodwill, rights and claims, other than certain excluded assets, all as more specifically set forth in the Applied Purchase Agreement (collectively, the “Applied Purchased Assets”), and assumed certain Assumed Liabilities (as defined in the Applied Purchase Agreement), upon the terms and subject to the conditions set forth in the Applied Purchase Agreement (such transaction, the “Applied Asset Purchase”). The Applied Purchased Assets include the underlying intellectual property of, as well as the rights to manufacture and sell, certain hydrolyzed collagen products, including CellerateRX Surgical, for human wound care use. The Applied Purchased Assets were purchased for an initial aggregate purchase price of $ 15.25 9.75 73,809 3.0 2.5 625,000 Prior to the Closing, the Company licensed certain of its products from Applied through a sublicense agreement (the “Sublicense Agreement”) with CGI Cellerate RX, LLC (“CGI Cellerate RX”), a related party (see Note 11 for additional information regarding transactions with related parties). Pursuant to the Sublicense Agreement, the Company had an exclusive, world-wide sublicense to distribute certain hydrolyzed collagen products, including CellerateRX Surgical, into the surgical and wound care markets. In connection with the Applied Asset Purchase, Applied assigned its license agreement with CGI Cellerate RX to SMAT (the “License Agreement”), and on October 10, 2024, the License Agreement and the Sublicense Agreement were terminated for no additional consideration. In addition to the Cash Closing Consideration, Stock Closing Consideration and Installment Payments, the Applied Purchase Agreement provides that the Sellers are entitled to receive up to an additional $ 10.0 In connection with the Applied Asset Purchase and pursuant to the Applied Purchase Agreement, effective August 1, 2023, the Company entered into a professional services agreement (the “Petito Services Agreement”) with the Owner, pursuant to which the Owner, as an independent contractor, agreed to provide certain services to the Company, including, among other things, assisting with the development of products already in development and assisting with research, development, formulation, invention and manufacturing of any future products (the “Petito Services”). As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the term of the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of certain products the Owner develops or co-develops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for the first $50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half percent (2.5%) on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0 million, (iv) $500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0 million in cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments described in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million. The Petito Services Agreement has an initial term of three years and is subject to automatic successive one-month renewals unless earlier terminated in accordance with its terms. The Petito Services Agreement may be terminated upon the Owner’s death or disability or by the Company or the Owner “For Cause” (as defined in the Petito Services Agreement); provided, however, that the base salary described in (i) of the foregoing paragraph shall survive termination through the three-year initial term and the royalty payments and incentive payments described in (ii)-(v) of the foregoing paragraph shall survive termination of the Petito Services Agreement. As the contingent consideration was negotiated as part of the transfer of assets, the contingent obligation was measured at fair value and included in the total purchase consideration transferred. Accordingly, since the Applied Asset Purchase was accounted for as an asset acquisition and did not include contingent shares, the contingent consideration is classified as a liability at its estimated fair value at each reporting period with subsequent revaluations recognized as an adjustment to the intellectual property intangible asset and the earnout liability with a cumulative catch-up amortization adjustment. The total purchase consideration for the Applied Asset Purchase as determined by the Company was as follows: SCHEDULE OF ASSET PURCHASE CONSIDERATIONS Consideration Equity Shares Dollar Value Cash Closing Consideration $ 9,750,000 Fair value of Stock Closing Consideration 73,809 3,089,645 Fair value of Installment Payments 2,040,808 Cash paid for inventory 30,007 Fair value of Petito Services Agreement defined payments 825,834 Fair value of Petito Services Agreement contingent consideration 893,000 Direct transaction costs 162,743 Total purchase consideration $ 16,792,037 Based on guidance provided by ASC 805, Business Combinations (“ASC 805”), the Company recorded the Applied Asset Purchase as an asset acquisition due to the determination that substantially all the fair value of the assets acquired was concentrated in a group of similar identifiable assets. The Company believes the “substantially all” criterion was met with respect to the acquired intellectual property being the only significant asset acquired. Accordingly, the Company accounted for the transaction as an asset acquisition. The purchase consideration, plus transaction costs, was allocated to the individual assets according to their fair values as a percentage of the total fair value of the assets purchased, with no goodwill recognized. Based on the estimated fair value of the gross assets acquired, the total fair value of the net assets acquired was primarily attributable to, and classified as, finite-lived intellectual property in the third quarter of 2023. The total purchase consideration was allocated based on the relative estimated fair value of such assets as follows: SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED Description Amount Inventory $ 30,007 Equipment 33,062 Intellectual property 16,728,968 Net assets acquired $ 16,792,037

CONVERTIBLE LOAN RECEIVABLE

CONVERTIBLE LOAN RECEIVABLE	9 Months Ended
	Sep. 30, 2024
Receivables [Abstract]
CONVERTIBLE LOAN RECEIVABLE	NOTE 4 – CONVERTIBLE LOAN RECEIVABLE In connection with a potential equity investment in an unaffiliated entity engaged in the development of certain surgical technologies, the Company entered into a convertible loan agreement in July 2024 pursuant to which the Company loaned $ 1,079,391 to the unaffiliated entity. The loan was initially set to be repaid on October 1, 2024 However, the Company extended the repayment date to December 1, 2024 . On October 1, 2024, the loan began bearing interest at 8 % per annum. Pursuant to the convertible loan agreement, the Company has the option to convert the outstanding balance of the loan into noncontrolling equity interests of the unaffiliated entity upon satisfactory completion of certain due diligence activities. The loan is recorded under the caption “Convertible loan receivable” on the Company’s Consolidated Balance Sheets, which was $ 1,079,391 as of September 30, 2024.

GOODWILL AND INTANGIBLES, NET

GOODWILL AND INTANGIBLES, NET	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLES, NET	NOTE 5 – GOODWILL AND INTANGIBLES, NET The changes in the carrying amount of the Company’s goodwill were as follows: SCHEDULE OF CHANGES IN CARRYING AMOUNT OF GOODWILL Total Balance as of December 31, 2022 $ 3,601,781 Acquisitions - Balance as of December 31, 2023 3,601,781 Balance 3,601,781 Acquisitions - Balance as of September 30, 2024 $ 3,601,781 Balance $ 3,601,781 In connection with the change in reportable operating segments, the Company reassessed goodwill with respect to the change in reportable operating segments as they are presented in this report. Goodwill was recorded in connection with the acquisition of Scendia and is included entirely within the Sanara Surgical segment. The Company’s assessment determined that these changes, or any other matters noted, did not alter the Company’s conclusion that goodwill is not impaired as of September 30, 2024 or for the periods then ended. The carrying values of the Company’s intangible assets were as follows for the periods presented: SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS September 30, 2024 December 31, 2023 Accumulated Accumulated Cost Amortization Net Cost Amortization Net Amortizable Intangible Assets: Patents and Other IP $ 38,592,549 $ (4,934,785 ) $ 33,657,764 $ 38,570,549 $ (3,181,186 ) $ 35,389,363 Customer relationships and other 7,947,332 (2,737,675 ) 5,209,657 7,947,332 (1,861,887 ) 6,085,445 Product Licenses 4,793,879 (1,632,158 ) 3,161,721 4,793,879 (1,342,626 ) 3,451,253 Total $ 51,333,760 $ (9,304,618 ) $ 42,029,142 $ 51,311,760 $ (6,385,699 ) $ 44,926,061 As of September 30, 2024, the weighted-average amortization period for finite-lived intangible assets was 14.5 974,262 881,079 2,918,919 2,247,482 SCHEDULE OF FUTURE AMORTIZATION EXPENSE Remainder of 2024 $ 972,818 2025 3,891,270 2026 3,874,015 2027 3,760,162 2028 3,726,921 2029 3,726,921 Thereafter 22,077,035 Total $ 42,029,142 The Company has reviewed the carrying value of intangible assets and has determined there was no impairment during the nine months ended September 30, 2024 or 2023.

INVESTMENTS IN EQUITY SECURITIE

INVESTMENTS IN EQUITY SECURITIES	9 Months Ended
	Sep. 30, 2024
Schedule of Investments [Abstract]
INVESTMENTS IN EQUITY SECURITIES	NOTE 6 – INVESTMENTS IN EQUITY SECURITIES The Company’s equity investments consist of nonmarketable equity securities in privately held companies without readily determinable fair values. Unless accounted for under the equity method of accounting, the investments are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. DirectDerm In July 2020, the Company made a $ 500,000 7,142,857 2.9 3,571,430 250,000 3,571,429 250,000 8.1 Pixalere In June 2021, the Company invested $ 2,084,278 278,587 27.3 27.3 93,879 The Company reviewed the characteristics of the Pixalere Shares in accordance with ASC Topic 323, Investments – Equity Method and Joint Ventures (“ASC 323”). Due to the substantive liquidation preferences of the Pixalere Shares over Pixalere’s common stock, the Pixalere Shares are not “in-substance” common stock, and therefore, the Company does not utilize the equity method of accounting for this investment. In accordance with ASC 321, this investment was reported at cost as of September 30, 2024. ChemoMouthpiece In September 2024, the Company, through its wholly owned subsidiary, Sanara CMP LLC (“Sanara CMP”), entered into a Unit Purchase Agreement (the “Unit Purchase Agreement”) with ChemoMouthpiece, LLC (“CMp”), pursuant to which Sanara CMP purchased 100,674.72 5.0 6.64 The Company has reviewed the characteristics of Sanara CMP’s investment in CMp in accordance with ASC 323 and determined that Sanara CMP made a non-controlling investment in a limited liability company. According to the guidance provided in ASC 323-30-S99-1, investments in limited liability companies whereby an investor holds more than a 3% to 5% ownership interest would generally be accounted for under the equity method of accounting. Therefore, the Company utilized the equity method of accounting for this investment and recorded its initial investment at cost. Sanara CMP’s share of the earnings or losses of CMp is recorded in the Company’s Consolidated Statements of Operations. The following table summarizes the Company’s investments for the periods presented: SCHEDULE OF INVESTMENTS September 30, 2024 December 31, 2023 Carrying Amount Economic Interest Carrying Amount Economic Interest Equity Method Investment ChemoMouthpiece, LLC $ 5,237,134 6.64 % $ - - % Cost Method Investments Direct Dermatology, Inc. $ 1,000,000 $ 1,000,000 Pixalere Healthcare Inc. 2,084,278 2,084,278 Total Cost Method Investments $ 3,084,278 $ 3,084,278 Total Investments $ 8,321,412 $ 3,084,278 The following table summarizes the Company’s share of losses from equity method investment reflected in the Company’s Consolidated Statements of Operations for the periods presented: SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT 2024 2023 2024 2023 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Investment ChemoMouthpiece, LLC $ (31,448 ) $ - $ (31,448 ) $ - Total $ (31,448 ) $ - $ (31,448 ) $ - Loss from equity method investment $ (31,448 ) $ - $ (31,448 ) $ -

OPERATING LEASES

OPERATING LEASES	9 Months Ended
	Sep. 30, 2024
Operating Leases
OPERATING LEASES	NOTE 7 – OPERATING LEASES The Company periodically enters operating lease contracts for office space and equipment. Arrangements are evaluated at inception to determine whether such arrangements constitute a lease. Right of use assets (“ROU assets”) represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized on the transition date based on the present value of lease payments over the respective lease term, with the office space ROU asset adjusted for deferred rent liability. The Company has three material operating leases for office space. In March and September of 2023, the Company amended its primary office lease to obtain additional space, as well as extend the term. The leases have remaining lease terms of 75 11 28 In accordance with ASC Topic 842, Leases, the Company has recorded ROU assets of $ 1,688,963 1,846,293 121,126 110,693 416,394 295,268 362,491 264,291 The present value of the Company’s operating lease liabilities as of September 30, 2024 is shown below: Maturity of Operating Lease Liabilities SCHEDULE OF OPERATING LEASE LIABILITY September 30, Remainder of 2024 $ 142,525 2025 532,053 2026 379,529 2027 297,947 2028 295,689 2029 300,158 Thereafter 303,892 Total lease payments 2,251,793 Less imputed interest (405,500 ) Present Value of Lease Liabilities $ 1,846,293 Operating lease liabilities – current $ 439,129 Operating lease liabilities – long-term $ 1,407,164 As of September 30, 2024, the Company’s operating leases had a weighted average remaining lease term of 5.4 7.66

DEBT AND CREDIT FACILITIES

DEBT AND CREDIT FACILITIES	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
DEBT AND CREDIT FACILITIES	NOTE 8 – DEBT AND CREDIT FACILITIES CRG Term Loan Agreement On April 17, 2024 (the “Closing Date”), the Company entered into a term loan agreement, by and among the Company, as borrower, the subsidiary guarantors party thereto from time to time (collectively, the “Guarantors”), CRG Servicing LLC as administrative agent and collateral agent (the “Agent”), and the lenders party thereto from time to time (the “CRG Term Loan Agreement”), providing for a senior secured term loan of up to $ 55.0 15.0 40.0 each such borrowing must be at least $5.0 million or a multiple of $5.0 million and occur between the Closing Date and June 30, 2025, On September 4, 2024, the Company, pursuant to its option under the CRG Term Loan Agreement, borrowed an additional $ 15.5 5.0 The First Borrowing, Second Borrowing and any additional borrowings under the CRG Term Loan are due and payable on March 30, 2029 The CRG Term Loan bears interest at a per annum rate equal to 13.25 4.0 8.00 5.25 th 1.50 7.00 For the three months ended September 30, 2024, the Company paid $ 399,532 262,193 646,199 424,068 167,189 219,689 Subject to certain exceptions, the Company is required to make mandatory prepayments of the CRG Term Loan with the proceeds of certain assets sales and in the event of a change of control of the Company. In addition, the Company may make a voluntary prepayment of the CRG Term Loan, in whole or in part, at any time. All mandatory and voluntary prepayments of the CRG Term Loan are subject to the payment of prepayment premiums as follows: (i) if prepayment occurs on or prior to the date that is one year following the applicable borrowing (the “Borrowing Date”), an amount equal to 10.0% of the aggregate outstanding principal amount of the CRG Term Loan being prepaid and (ii) if prepayment occurs one year after the applicable Borrowing Date and on or prior to two years following the applicable Borrowing Date, an amount equal to 5.0% of the aggregate outstanding principal amount of the CRG Term Loan being prepaid. Certain of the Company’s current and future subsidiaries, including the Guarantors, are guaranteeing the obligations of the Company under the CRG Term Loan Agreement. As security for their obligations under the CRG Term Loan Agreement, on the Closing Date, the Company and the Guarantors entered into a security agreement with the Agent pursuant to which the Company and the Guarantors granted to the Agent, as collateral agent for the lenders, a lien on substantially all of the Company’s and the Guarantors’ assets, including intellectual property (subject to certain exceptions). The CRG Term Loan Agreement contains affirmative and negative covenants customary for financings of this type, including limitations on the Company’s and the Guarantors’ abilities, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions above certain thresholds, merge or consolidate with others, dispose of assets, pay dividends and distributions and enter into affiliate transactions, in each case, subject to certain exceptions. In addition, the CRG Term Loan Agreement contains the following financial covenants requiring the Company and the Guarantors in the aggregate to maintain: ● liquidity in an amount which shall exceed the greater of (i) $ 3.0 ● annual minimum revenue: (i) for the twelve-month period beginning on January 1, 2024 and ending on December 31, 2024, of at least $ 60.0 75.0 85.0 95.0 105.0 The CRG Term Loan Agreement contains representations and warranties of the Company and the Guarantors customary for financings of this type, and also includes events of default customary for financings of this type, including, among other things, non-payment, inaccuracy of representations and warranties, covenant breaches, a material adverse change, bankruptcy and insolvency, material judgments and a change of control, in certain cases subject to customary periods to cure. The occurrence and continuance of an event of default could result in the acceleration of the obligations under the CRG Term Loan Agreement. Cadence Term Loan In connection with the entry into the Applied Purchase Agreement, on August 1, 2023, SMAT, as borrower, and the Company, as guarantor, entered into a loan agreement (the “Cadence Loan Agreement”) with Cadence Bank (the “Bank”) providing for, among other things, an advancing term loan in the aggregate principal amount of $ 12.0 The proceeds of the advances under the Cadence Loan Agreement were used for working capital and for purposes of financing up to one hundred percent ( 100 9.75 The unpaid principal balance of outstanding advances bore interest, subject to certain conditions, at the lesser of the Maximum Rate (as defined in the Cadence Loan Agreement) or the Base Rate, which was for any day, a rate per annum equal to the term secured overnight financing rate (Term SOFR) (as administered by the Federal Reserve Bank of New York) for a one-month tenor in effect on such day plus three percent ( 3.0 8.3 On the Closing Date, the Cadence Loan Agreement was terminated and all outstanding amounts under the Cadence Term Loan were repaid in full and all security interest and other liens granted to or held by Cadence were terminated and released. In addition, unamortized debt issuance costs as of the termination date of $ 53,438 The table below presents the components of the Company’s outstanding debt for the periods presented: SCHEDULE OF LONG-TERM DEBT September 30, December 31, CRG Term Loan $ 30,500,000 $ - Paid-in-kind interest 424,067 - Back-end fee 219,689 - Cadence Term Loan - 9,750,000 Debt 31,143,756 9,750,000 Less: unamortized debt issuance costs (1,067,041 ) (56,520 ) Debt, net of debt issuance costs 30,076,715 9,693,480 Less: Current portion of debt - 580,357 Long-term debt, net of current portion $ 30,076,715 $ 9,113,123 The table below presents the aggregate maturities of the Company’s outstanding debt as of September 30, 2024: SCHEDULE OF MATURITIES OUTSTANDING Year Total Remainder of 2024 $ - 2025 - 2026 - 2027 - 2028 - Thereafter 31,143,756 Total debt $ 31,143,756 In connection with the CRG Term Loan, the Company incurred $ 1,160,740 273,487 1,067,041 56,520 150,219 2,055 56,520

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 - COMMITMENTS AND CONTINGENCIES License Agreements and Royalties CellerateRX Surgical In August 2018, the Company entered an exclusive, world-wide sublicense agreement with CGI Cellerate RX to distribute certain hydrolyzed collagen products, including CellerateRX Surgical, into the surgical and wound care markets. Pursuant to the Sublicense Agreement, the Company paid royalties of 3-5% of annual collected net sales of these products. As amended in January 2021, the term of the sublicense was extended through May 2050, with automatic successive year-to-year renewal terms thereafter so long as the Company’s Net Sales (as defined in the Sublicense Agreement) each year are equal to or in excess of $1,000,000. If the Company’s Net Sales fall below $1,000,000 for any year after the expiration date, CGI Cellerate RX has the right to terminate the Sublicense Agreement upon written notice. Under this agreement, royalty expense, which was recorded in “Cost of goods sold” in the accompanying Consolidated Statements of Operations, totaled zero 9,209 zero 1,060,035 As discussed further in Note 3, on August 1, 2023, the Company purchased certain assets from Applied, including the rights to manufacture and sell certain hydrolyzed collagen products, including CellerateRX Surgical, for use in the human wound care market. In connection with the Applied Asset Purchase, Applied assigned the License Agreement with CGI Cellerate RX to SMAT, and on October 10, 2024, the License Agreement and Sublicense Agreement were terminated. BIAKŌS Antimicrobial Wound Gel and BIAKŌS Antimicrobial Skin and Wound Cleanser In July 2019, the Company executed a license agreement with Rochal Industries, LLC (“Rochal”), a related party, pursuant to which the Company acquired an exclusive world-wide license to market, sell and further develop antimicrobial products for the prevention and treatment of microbes on the human body utilizing certain Rochal patents and pending patent applications (the “BIAKŌS License Agreement”). Currently, the products covered by the BIAKŌS License Agreement are BIAKŌS Antimicrobial Wound Gel, BIAKŌS Antimicrobial Skin and Wound Cleanser and BIASURGE Advanced Surgical Solution. All three products are 510(k) cleared. Future commitments under the terms of the BIAKŌS License Agreement include: ● The Company pays Rochal a royalty of 2 - 4 % of net sales. The minimum annual royalty due to Rochal was $ 146,410 for 2024 and will increase to a maximum amount of $ 150,000 in 2025. ● The Company may pay additional royalties annually based on specific net profit targets from sales of the licensed products, subject to a maximum of $ 1,000,000 Unless previously terminated by the parties, the BIAKŌS License Agreement expires with the related patents in December 2031. Under this agreement, royalty expense, which is recorded in “Cost of goods sold” in the accompanying Consolidated Statements of Operations, was $ 36,602 32,499 113,907 97,499 CuraShield Antimicrobial Barrier Film and No Sting Skin Protectant In October 2019, the Company executed a license agreement with Rochal pursuant to which the Company acquired an exclusive world-wide license to market, sell and further develop certain antimicrobial barrier film and skin protectant products for use in the human health care market utilizing certain Rochal patents and pending patent applications (the “ABF License Agreement”). Currently, the products covered by the ABF License Agreement are CuraShield Antimicrobial Barrier Film and a no sting skin protectant product. Future commitments under the terms of the ABF License Agreement include: ● The Company will pay Rochal a royalty of 2 4 50,000 10 75,000 ● The Company will pay additional royalties annually based on specific net profit targets from sales of the licensed products, subject to a maximum of $ 500,000 Unless previously terminated or extended by the parties, the ABF License Agreement will terminate upon expiration of the last U.S. patent in October 2033. No commercial sales or royalties have been recognized under this agreement as of September 30, 2024. Debrider License Agreement In May 2020, the Company executed a product license agreement with Rochal, pursuant to which the Company acquired an exclusive world-wide license to market, sell and further develop a debrider for human medical use to enhance skin condition or treat or relieve skin disorders, excluding uses primarily for beauty, cosmetic, or toiletry purposes (the “Debrider License Agreement”). Future commitments under the terms of the Debrider License Agreement include: ● Upon FDA clearance of the licensed products, the Company will pay Rochal $ 500,000 1,000,000 ● The Company will pay Rochal a royalty of 2 4 100,000 10 150,000 ● The Company will pay additional royalty annually based on specific net profit targets from sales of the licensed products, subject to a maximum of $ 1,000,000 Unless previously terminated or extended by the parties, the Debrider License Agreement will expire in October 2034. No commercial sales or royalties have been recognized under this agreement as of September 30, 2024. Rochal Asset Acquisition The Company entered into an asset purchase agreement with Rochal effective July 1, 2021, pursuant to which the Company purchased certain assets of Rochal. Pursuant to the asset purchase agreement, for the three-year period after the effective date, Rochal is entitled to receive consideration for any new product relating to the business that is directly and primarily based on an invention conceived and reduced to practice by a member or members of Rochal’s science team. For the three-year period after the effective date, Rochal is also entitled to receive an amount in cash equal to twenty-five percent of the proceeds received for any Grant (as defined in the asset purchase agreement) by either the Company or Rochal. In addition, the Company agreed to use commercially reasonable efforts to perform Minimum Development Efforts (as defined in the asset purchase agreement) with respect to certain products under development, which if obtained, will entitle the Company to intellectual property rights from Rochal in respect of such products. Precision Healing Merger Agreement In April 2022, the Company closed a merger transaction with Precision Healing pursuant to which Precision Healing became a wholly owned subsidiary of the Company. Pursuant to the terms of the merger agreement, holders of Precision Healing common stock and preferred stock, other than the Company, were entitled to receive closing consideration, consisting of $ 125,966 165,738 0.6 165,738 30.75 Upon the closing of the merger, the Precision Healing outstanding options previously granted under the Precision Healing Plan converted, pursuant to their terms, into options to acquire an aggregate of 144,191 10.71 4,424 7.32 April 22, 2031 12,301 12.05 August 10, 2030 Pursuant to the merger agreement, upon the achievement of certain performance thresholds, the securityholders of Precision Healing, including the holders of options and warrants to purchase Precision Healing common stock and certain persons promised options to purchase Precision Healing common stock, are also entitled to receive payments of up to $ 10.0 27.13 Scendia Purchase Agreement In July 2022, the Company closed the Scendia acquisition pursuant to which Scendia became a wholly owned subsidiary of the Company. Pursuant to the purchase agreement, the aggregate consideration for the acquisition at closing was approximately $ 7.6 1.6 291,686 94,798 In addition to the cash consideration and the stock consideration, the purchase agreement provides that Phillips is entitled to receive two potential earnout payments, payable on an annual basis, not to exceed $ 10.0 486,145 693,000 1.1 Applied Asset Purchase On August 1, 2023, the Company closed the Applied Asset Purchase. The Applied Purchased Assets were purchased for an initial aggregate purchase price of $ 15.25 In addition to the Cash Closing Consideration, Stock Closing Consideration and Installment Payments, the Applied Purchase Agreement provides that the Sellers are entitled to receive the Applied Earnout, which is payable to the Sellers in cash, upon the achievement of certain performance thresholds relating to SMAT’s collections from net sales of a collagen-based product currently under development. Upon expiration of the seventh anniversary of the Closing, to the extent the Sellers have not earned the entirety of the Applied Earnout, SMAT shall pay the Sellers the True-Up Payment. The Applied Earnout, minus the True-Up Payment and any Applied Earnout payments already made by SMAT, may be earned at any point in the future, including after the True-Up Payment is made. In connection with the Applied Asset Purchase and pursuant to the Applied Purchase Agreement, effective August 1, 2023, the Company entered into the Petito Services Agreement with the Owner, pursuant to which the Owner, as an independent contractor, agreed to provide the Petito Services. As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the term of the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of certain products the Owner develops or codevelops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for the first $50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half percent (2.5%) on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0 million, (iv) $500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0 million in cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments described in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million. The Petito Services Agreement has an initial term of three years and is subject to automatic successive one-month renewals unless earlier terminated in accordance with its terms. The Petito Services Agreement may be terminated upon the Owner’s death or disability or by the Company or the Owner “For Cause” (as defined in the Petito Services Agreement); provided, however, that the base salary described in (i) of the foregoing paragraph shall survive termination through the three-year initial term and the royalty payments and incentive payments described in (ii)-(v) of the foregoing paragraph shall survive termination of the Petito Services Agreement. Other Commitments On December 20, 2023, the Company signed an exclusive license agreement with Tufts University (“Tufts”) to develop and commercialize patented technology covering 18 unique collagen peptides. As part of this agreement, the Company formed a new subsidiary, Sanara Collagen Peptides, LLC (“SCP”) and 10 1.5 3 50,000 100,000

SHAREHOLDERS_ EQUITY

SHAREHOLDERS’ EQUITY	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
SHAREHOLDERS’ EQUITY	NOTE 10 – SHAREHOLDERS’ EQUITY Common Stock At the Company’s Annual Meeting of Shareholders held in July 2020, the Company approved the Restated 2014 Omnibus Long Term Incentive Plan (the “2014 LTIP”) in which the Company’s directors, officers, employees and consultants are eligible to participate. The 2014 LTIP terminated on September 3, 2024, and no future awards may be granted pursuant to the 2014 LTIP. Previously granted awards under the 2014 LTIP will remain outstanding until they expire by their terms or under the terms of the 2014 LTIP. On June 12, 2024, the Company’s shareholders approved the 2024 Omnibus Long-Term Incentive Plan (the “2024 LTIP”), which went into effect upon shareholder approval. The maximum number of shares of the Company’s common stock that may be delivered pursuant to awards granted under the 2024 LTIP is 1,000,000 745,085 1,000,000 In April 2022, the Company closed a merger transaction with Precision Healing pursuant to which Precision Healing became a wholly owned subsidiary of the Company. Pursuant to the terms of the merger agreement, holders of Precision Healing common stock and preferred stock, other than the Company, were entitled to receive closing consideration, consisting of $ 125,966 165,738 0.6 165,738 30.75 Upon the closing of the merger, the Precision Healing outstanding options previously granted under the Precision Healing Plan converted, pursuant to their terms, into options to acquire an aggregate of 144,191 10.71 4,424 7.32 April 22, 2031 12,301 12.05 August 10, 2030 Pursuant to the merger agreement, upon the achievement of certain performance thresholds, the securityholders of Precision Healing, including the holders of options and warrants to purchase Precision Healing common stock and certain persons promised options to purchase Precision Healing common stock, are also entitled to receive payments of up to $ 10.0 27.13 In July 2022, the Company closed the Scendia acquisition pursuant to which Scendia became a wholly owned subsidiary of the Company. Pursuant to the purchase agreement, the aggregate consideration at closing for the acquisition was approximately $ 7.6 1.6 291,686 94,798 In addition to the cash consideration and the stock consideration, the purchase agreement provides that Phillips is entitled to receive two potential earnout payments, payable on an annual basis, not to exceed $ 10.0 486,145 693,000 1.1 In February 2023, the Company entered into a Controlled Equity Offering SM 75,000,000 Sales of the shares were made in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Cantor agreed to use commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations and the rules of The Nasdaq Capital Market to sell the shares from time to time based upon the Company’s instructions, including any price, time period or size limits specified by the Company. The Company had no obligation to sell any of the shares under the Sales Agreement and could suspend or terminate the offering of its common stock pursuant to the Sales Agreement upon notice to Cantor and subject to other conditions. Cantor’s obligations to sell the shares under the Sales Agreement were subject to satisfaction of certain conditions, including customary closing conditions. Pursuant to the Sales Agreement, the Company paid Cantor a commission of 3.0 In 2023, the Company sold an aggregate of 26,143 1.1 0.9 On August 1, 2023, the Company closed the Applied Asset Purchase. Included in the purchase price was 73,809 Restricted Stock Awards During the nine months ended September 30, 2024, the Company issued restricted stock awards under the 2014 LTIP which are subject to certain vesting provisions and other terms and conditions set forth in each recipient’s respective restricted stock agreement. The Company granted and issued 164,588 5,765,952 Share-based compensation expense of $ 1,025,430 857,526 3,240,361 2,582,163 At September 30, 2024, there was $ 5,403,255 0.7 Below is a summary of restricted stock activity for the nine months ended September 30, 2024: SUMMARY OF RESTRICTED STOCK ACTIVITY For the Nine Months Ended September 30, 2024 Shares Weighted Average Grant Date Fair Value Nonvested at beginning of period 144,211 $ 34.07 Granted 190,240 35.03 Vested (84,407 ) 33.26 Forfeited (25,652 ) 35.02 Nonvested at September 30, 2024 224,392 $ 35.08 Stock Options A summary of the status of outstanding stock options at September 30, 2024 and changes during the nine months then ended is presented below: SCHEDULE OF STOCK OPTION ACTIVITY For the Nine Months Ended September 30, 2024 Weighted Average Weighted Average Aggregate Exercise Remaining Intrinsic Options Price Contract Life Value Outstanding at beginning of period 93,892 $ 10.22 Granted or assumed - - Exercised (62,879 ) 10.05 Forfeited - - Expired - - Outstanding at September 30, 2024 31,013 $ 10.57 6.1 $ 547,530.6 Exercisable at September 30, 2024 31,013 $ 10.57 6.1 $ 547,530.6 Warrants A summary of the status of outstanding warrants to purchase common stock at September 30, 2024 and changes during the nine months then ended is presented below: SCHEDULE OF WARRANTS TO PURCHASE COMMON STOCK For the Nine Months Ended September 30, 2024 Weighted Average Weighted Average Exercise Remaining Warrants Price Contract Life Outstanding at beginning of period 16,725 $ 10.80 Granted or assumed - - Exercised - - Forfeited - - Expired - - Outstanding at September 30, 2024 16,725 $ 10.80 6.0 Exercisable at September 30, 2024 16,725 $ 10.80 6.0

RELATED PARTIES

RELATED PARTIES	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTIES	NOTE 11 – RELATED PARTIES CellerateRX Sublicense Agreement The Company had an exclusive, world-wide sublicense to distribute certain hydrolyzed collagen products, including CellerateRX Surgical into the surgical and wound care markets from an affiliate of The Catalyst Group, Inc. (“Catalyst”), CGI Cellerate RX, which licensed the rights to these products from Applied. Sales of CellerateRX Surgical have comprised the substantial majority of the Company’s sales during the nine months ended September 30, 2024 and 2023. As amended in January 2021, the term of the Sublicense Agreement was extended through May 2050, with automatic successive one-year renewals so long as annual net sales of the licensed products exceed $ 1,000,000 As discussed further in Note 3, on August 1, 2023, the Company purchased certain assets from Applied, including the underlying intellectual property of, as well as the rights to manufacture and sell certain hydrolyzed collagen products, including CellerateRX Surgical. In connection with the Applied Asset Purchase, Applied assigned the License Agreement with CGI Cellerate RX to SMAT, and on October 10, 2024, the License Agreement and Sublicense Agreement were terminated. Ronald T. Nixon, the Company’s Chief Executive Officer and Executive Chairman, is the founder and managing partner of Catalyst. Product License Agreements In July 2019, the Company executed a license agreement with Rochal, a related party, whereby the Company acquired an exclusive world-wide license to market, sell and further develop antimicrobial products for the prevention and treatment of microbes on the human body utilizing certain Rochal patents and pending patent applications. Currently, the products covered by the BIAKŌS License Agreement are BIAKŌS Antimicrobial Wound Gel and BIAKŌS Antimicrobial Skin and Wound Cleanser. Both products are 510(k) cleared. Mr. Nixon is a director of Rochal, and indirectly a significant shareholder of Rochal, and through the potential exercise of warrants, a majority shareholder of Rochal. Another one of the Company’s directors is also a director and significant shareholder of Rochal. In October 2019, the Company executed the ABF License Agreement with Rochal whereby the Company acquired an exclusive world-wide license to market, sell and further develop certain antimicrobial barrier film and skin protectant products for use in the human health care market utilizing certain Rochal patents and pending patent applications. Currently, the products covered by the ABF License Agreement are CuraShield Antimicrobial Barrier Film and a no sting skin protectant product. In May 2020, the Company executed a product license agreement with Rochal, whereby the Company acquired an exclusive world-wide license to market, sell and further develop a debrider for human medical use to enhance skin condition or treat or relieve skin disorders, excluding uses primarily for beauty, cosmetic, or toiletry purposes. See Note 9 for more information on these product license agreements. Consulting Agreement Concurrent with the Rochal asset purchase, in July 2021, the Company entered into a consulting agreement with Ann Beal Salamone pursuant to which Ms. Salamone agreed to provide the Company with consulting services with respect to, among other things, writing new patents, conducting patent intelligence, and participating in certain grant and contract reporting. In consideration for the consulting services to be provided to the Company, Ms. Salamone is entitled to receive an annual consulting fee of $ 177,697 Catalyst Transaction Advisory Services Agreement In March 2023, the Company entered into a Transaction Advisory Services Agreement (the “Catalyst Services Agreement”) effective March 1, 2023 with Catalyst, a related party. Pursuant to the Catalyst Services Agreement, Catalyst, by and through its directors, officers, employees and affiliates that are not simultaneously serving as directors, officers or employees of the Company (collectively, the “Covered Persons”), agreed to perform certain transaction advisory, business and organizational strategy, finance, marketing, operational and strategic planning, relationship access and corporate development services for the Company in connection with any merger, acquisition, recapitalization, divestiture, financing, refinancing, or other similar transaction in which the Company may be, or may consider becoming, involved, and any such additional services as mutually agreed upon in writing by and between Catalyst and the Company (the “Catalyst Services”). Pursuant to the Catalyst Services Agreement, the Company agreed to reimburse Catalyst for (i) compensation actually paid by Catalyst to any of the Covered Persons at a rate no more than a rate consistent with industry practice for the performance of services similar to the Catalyst Services, as documented in reasonably sufficient detail, and (ii) all reasonable out-of-pocket costs and expenses payable to unaffiliated third parties, as documented in customary expense reports, as each of (i) and (ii) is incurred in connection with the Catalyst Services rendered under the Catalyst Services Agreement, with all reimbursements being contingent upon the prior approval of the Audit Committee of the Company’s Board of Directors. The Company incurred costs pursuant to the Catalyst Services Agreement of $ 49,829 44,032 163,101 117,018

SEGMENT REPORTING

SEGMENT REPORTING	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE 12 – SEGMENT REPORTING As discussed in Note 1, the Company historically managed its business on the basis of one two Segment EBITDA is the primary profitability measure used by the CODM for purposes of assessing financial performance and resource allocation. The Company defines Segment EBITDA for the reportable segments as net income (loss) excluding interest expense/income, provision/benefit for income taxes, depreciation and amortization, non-cash share-based compensation expense, change in fair value of earnout liabilities, share of losses from equity method investment, executive separation costs, legal and diligence expenses related to acquisitions, and gains/losses on disposal of property and equipment as each are applicable to the periods presented. Segment EBITDA, as it relates to the Company’s reportable segments, is presented in conformity with ASC 280, Segment Reporting, and is excluded from the definition of non-GAAP financial measures under the Securities and Exchange Commission’s Regulation G and Item 10(e) of Regulation S-K. Segment EBITDA may not be comparable to similarly titled measures reported by other companies. Sanara Surgical The Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Sanara Surgical’s soft tissue repair products include, among other products, the Company’s lead product, CellerateRX Surgical, and BIASURGE Advanced Surgical Solution, which is a no-rinse, advanced surgical solution used for wound irrigation. Sanara Surgical’s bone fusion products include, among other products, BiFORM, which is an osteoconductive, bioactive, porous implant that allows for bony ingrowth across the graft site, and ALLOCYTE Plus, which is a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers. Sanara Surgical also includes an in-house research and development team (Rochal Technologies) with an extensive pipeline of innovative products under development. Tissue Health Plus The THP segment is focused on value-based wound care services. Through THP, the Company plans to offer a first of its kind value-based wound care program to payers and risk-bearing entities such as accountable care organizations and VBC primary care companies, with Medicare Advantage payers as the initial target market for this program. THP’s programs are expected to enable payers to divest wound care spend risk, reduce wound related hospitalizations and improve patient quality of life. THP plans to coordinate delivery of community and home-based wound care for its managed patients. Community based care spans a variety of settings including physician offices, skilled nursing facilities, assisted living facilities and senior living facilities. THP programs are intended to integrate science and evidence-based medicine protocols to standardize wound prevention and treatment. Currently, there are no allocated costs included in the THP segment. All corporate and overhead expenses are included in the Sanara Surgical segment, as substantially all of those costs relate to supporting the operations and activities of the Sanara Surgical segment. As a result of the change in reportable segments, certain prior period amounts have been recast to conform to the current period presentation. Throughout this Quarterly Report on Form 10-Q, unless otherwise indicated, amounts and activity reflect reclassifications related to the Company’s change in reportable segments. The change in reportable segments had no impact on the Company’s previously reported Consolidated Balance Sheets, Consolidated Statements of Operations, Consolidated Statements of Cash Flows or Consolidated Statements of Shareholders’ Equity. The following tables reflect results of operations, Segment EBITDA, segmented assets, and expenditures for long-lived assets for the Company’s reportable segments for the periods indicated below: SCHEDULE OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS Sanara Surgical THP Total Sanara Surgical THP Total Three Months Ended September 30, 2024 2023 Sanara Surgical THP Total Sanara Surgical THP Total Net revenue $ 21,671,599 $ - $ 21,671,599 $ 16,024,948 $ - $ 16,024,948 Gross profit 19,679,612 - 19,679,612 14,273,599 - 14,273,599 Selling, general and administrative expenses 17,420,346 1,572,909 18,993,255 13,460,404 417,475 13,877,879 Research and development 783,840 575,690 1,359,530 225,886 760,568 986,454 Depreciation and amortization 696,888 406,966 1,103,854 590,563 407,111 997,674 Interest expense 927,577 - 927,577 188,294 - 188,294 Net income (loss) (180,488 ) (2,702,564 ) (2,883,052 ) 567,235 (1,662,184 ) (1,094,949 ) Segment EBITDA 2,563,521 (1,721,560 ) 841,961 1,400,916 (1,134,124 ) 266,792 Segment assets (at period end) (1) $ 67,037,973 $ 21,507,503 $ 88,545,476 $ 45,715,495 $ 28,155,654 $ 73,871,149 Expenditures for long-lived assets $ 9,096 $ - $ 9,096 $ 170,320 $ - $ 170,320 Sanara Surgical THP Total Sanara Surgical THP Total Nine Months Ended September 30, 2024 2023 Sanara Surgical THP Total Sanara Surgical THP Total Net revenue $ 60,367,060 $ - $ 60,367,060 $ 47,297,299 $ 2,730 $ 47,300,029 Gross profit (loss) 54,476,341 - 54,476,341 41,241,740 (6,235 ) 41,235,505 Selling, general and administrative expenses 51,453,311 2,689,811 54,143,122 39,229,030 1,429,394 40,658,424 Research and development 1,945,263 1,346,216 3,291,479 669,849 2,811,057 3,480,906 Depreciation and amortization 2,093,797 1,220,984 3,314,781 1,359,180 1,221,063 2,580,243 Interest expense 1,839,259 - 1,839,259 188,300 - 188,300 Net income (loss) (2,872,286 ) (5,339,011 ) (8,211,297 ) 1,181,296 (5,358,754 ) (4,177,458 ) Segment EBITDA 5,095,670 (3,350,104 ) 1,745,566 3,766,196 (4,087,858 ) (321,662 ) Segment assets (at period end) (1) $ 67,037,973 $ 21,507,503 $ 88,545,476 $ 45,715,495 $ 28,155,654 $ 73,871,149 Expenditures for long-lived assets $ 133,676 $ - $ 133,676 $ 210,970 $ - $ 210,970 (1) - Segment assets for 2023 represent assets as of December 31, 2023. The following tables provide a reconciliation of net income (loss) to Segment EBITDA for the Company’s reportable segments for the periods indicated below: SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS Sanara Surgical THP Total Sanara Surgical THP Total Three Months Ended September 30, 2024 2023 Sanara Surgical THP Total Sanara Surgical THP Total Net Income (Loss) $ (180,488 ) $ (2,702,564 ) $ (2,883,052 ) $ 567,235 $ (1,662,184 ) $ (1,094,949 ) Adjustments: Interest expense 927,577 - 927,577 188,294 - 188,294 Depreciation and amortization 696,888 406,966 1,103,854 590,563 407,111 997,674 Noncash share-based compensation 1,003,599 21,831 1,025,430 813,606 43,920 857,526 Change in fair value of earnout liabilities - 147,000 147,000 (758,783 ) 77,030 (681,753 ) Share of losses from equity method investment 31,448 - 31,448 - - - Executive separation costs 59,685 - 59,685 - - - Acquisition costs 24,812 405,207 430,019 - - - Segment EBITDA $ 2,563,521 $ (1,721,560 ) $ 841,961 $ 1,400,916 $ (1,134,124 ) $ 266,792 Sanara Surgical THP Total Sanara Surgical THP Total Nine Months Ended September 30, 2024 2023 Sanara Surgical THP Total Sanara Surgical THP Total Net Income (Loss) $ (2,872,286 ) $ (5,339,011 ) $ (8,211,297 ) $ 1,181,296 $ (5,358,754 ) $ (4,177,458 ) Adjustments: Interest expense 1,839,259 - 1,839,259 188,300 - 188,300 Depreciation and amortization 2,093,797 1,220,984 3,314,781 1,359,180 1,221,063 2,580,243 Noncash share-based compensation 2,803,536 108,031 2,911,567 2,423,335 158,828 2,582,163 Change in fair value of earnout liabilities (14,451 ) 82,000 67,549 (1,385,914 ) (108,996 ) (1,494,910 ) Share of losses from equity method investment 31,448 - 31,448 - - - Executive separation costs (1) 964,466 - 964,466 - - - Acquisition costs 249,901 577,892 827,793 - - - Segment EBITDA $ 5,095,670 $ (3,350,104 ) $ 1,745,566 $ 3,766,196 $ (4,087,858 ) $ (321,662 ) (1) - Includes $ 328,795

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The accompanying unaudited consolidated financial statements include the accounts of Sanara MedTech Inc. and its wholly owned and majority-owned subsidiaries, as well as other entities in which the Company has a controlling financial interest. All significant intercompany profits, losses, transactions and balances have been eliminated in consolidation. Certain prior year amounts have been reclassified to conform to the current year presentation. The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management of the Company, all adjustments (consisting of normal accruals) considered necessary for a fair presentation have been included. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full year period. These financial statements and notes should be read in conjunction with the financial statements for each of the two years ended December 31, 2023 and 2022, which are included in the Company’s most recent Annual Report on Form 10-K.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported revenue and expenses during the reporting period. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
Income/Loss Per Share	Income/Loss Per Share The Company computes income/loss per share in accordance with Accounting Standards Codification (“ASC”) Topic 260, Earnings per Share, which requires the Company to present basic and diluted income per share when the effect is dilutive. Basic income/loss per share is computed by dividing income/loss attributable to common shareholders by the weighted average number of shares of common stock outstanding. Diluted income/loss per share is computed similarly to basic income/loss per share, except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. All common stock equivalents were excluded from the calculations for the periods presented as their inclusion would have been anti-dilutive during the three and nine months ended September 30, 2024 and 2023 due to the Company’s net loss. The following table summarizes the shares of common stock that were potentially issuable but were excluded from the computation of diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 as such shares would have had an anti-dilutive effect: SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE 2024 2023 As of September 30, 2024 2023 Stock options (a) 31,013 95,873 Warrants (b) 16,725 16,725 Unvested restricted stock 224,392 159,557 Anti-dilutive securities 224,392 159,557 (a) Shares underlying stock options assumed pursuant to the merger agreement with Precision Healing, Inc. (“Precision Healing”) in April 2022. (b) Shares underlying warrants assumed pursuant to the merger agreement with Precision Healing in April 2022.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when a purchase order is received from the customer and control of the promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for transferring those goods or services. Revenue is recognized based on the following five-step model: - Identification of the contract with a customer - Identification of the performance obligations in the contract - Determination of the transaction price - Allocation of the transaction price to the performance obligations in the contract - Recognition of revenue when, or as, the Company satisfies a performance obligation Details of this five-step process are as follows: Identification of the contract with a customer Customer purchase orders are generally considered to be contracts under ASC 606. Purchase orders typically identify the specific terms of products to be delivered, create the enforceable rights and obligations of both parties and result in commercial substance. No other forms of contract revenue recognition, such as the completed contract or percentage of completion methods, were utilized by the Company in either 2024 or 2023. Performance obligations The Company’s performance obligation is generally limited to delivery of the requested items to its customers at the agreed upon quantities and prices. Determination and allocation of the transaction price The Company has established prices for its products. These prices are effectively agreed to when customers place purchase orders with the Company. Rebates and discounts, if any, are recognized in full at the time of sale as a reduction of net revenue. Allocation of transaction prices is not necessary where only one performance obligation exists. Recognition of revenue as performance obligations are satisfied Product revenues are recognized when a purchase order is received from the customer, the products are delivered, and control of the goods and services passes to the customer. Disaggregation of Revenue Revenue streams from product sales and royalties are summarized below for the three and nine months ended September 30, 2024 and 2023. SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES 2024 2023 2024 2023 Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Soft tissue repair products $ 18,863,335 $ 13,634,316 $ 52,586,945 $ 39,756,539 Bone fusion products 2,808,264 2,340,382 7,779,209 7,392,740 Royalty revenue - 50,250 906 150,750 Total Net Revenue $ 21,671,599 $ 16,024,948 $ 60,367,060 $ 47,300,029 For the three and nine months ended September 30, 2024 and 2023, all of the Company’s net revenue was generated from Sanara Surgical. The Company plans to commercially launch the THP program in mid-2025.
Accounts Receivable Allowances	Accounts Receivable Allowances Accounts receivable are typically due within 30 days of invoicing. The Company establishes an allowance for credit losses to provide for an estimate of accounts receivable which are not expected to be collectible. The Company bases the allowance on an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and other information as applicable and will record its allowance based on the estimated credit losses. The Company recorded credit loss expense of $ 75,000 128,061 230,930 214,061 758,960 528,030 5,010 3,820
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value, with cost computed on a first-in, first-out basis. Inventories consist primarily of finished goods, and also include an immaterial amount of raw materials and related packaging components. The Company recorded inventory obsolescence expense of $ 96,684 152,701 356,261 222,691 466,276 446,917
Property and Equipment	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the related assets, ranging from two ten years SCHEDULE OF PROPERTY AND EQUIPMENT Useful September 30, December 31, Life 2024 2023 Computers 3 5 $ 235,388 $ 194,788 Office equipment 3 7 216,491 201,785 Furniture and fixtures 5 10 346,508 304,338 Leasehold improvements 2 5 170,370 134,170 Internal use software 5 1,618,999 1,618,999 Property and equipment, gross 2,587,756 2,454,080 Less accumulated depreciation (1,591,986 ) (1,196,124 ) Property and equipment, net $ 995,770 $ 1,257,956 Depreciation expense related to property and equipment was $ 129,592 116,596 395,862 332,762
Internal Use Software	Internal Use Software The Company accounts for costs incurred to develop or acquire computer software for internal use in accordance with ASC Topic 350-40, Intangibles – Goodwill and Other. The Company capitalizes the costs incurred during the application development stage, which generally includes third-party developer fees to design the software configuration and interfaces, coding, installation and testing. The Company begins capitalization of qualifying costs when both the preliminary project stage is completed and management has authorized further funding for the completion of the project. Costs incurred during the preliminary project stage along with post implementation stages of internal-use computer software are expensed as incurred. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized development costs are classified as “Property and equipment, net” in the Consolidated Balance Sheets and are depreciated over the estimated useful life of the software, which is generally five years
Goodwill	Goodwill The excess of purchase price over the fair value of identifiable net assets acquired in business combinations is recorded as goodwill. As of September 30, 2024 and December 31, 2023, all of the Company’s goodwill relates to the acquisition of Scendia Biologics, LLC (“Scendia”), which is included in the Sanara Surgical segment. Goodwill has an indefinite useful life and is not amortized. Goodwill is tested annually as of December 31 for impairment, or more frequently if circumstances indicate impairment may have occurred. The Company may first perform a qualitative assessment to determine if it is more likely than not that the fair value of the reporting unit is less than the respective carrying value. If it is determined that it is more likely than not that a reporting unit’s fair value is less than its carrying value, then the Company will determine the fair value of the reporting unit and record an impairment charge for the difference between fair value and carrying value (not to exceed the carrying amount of goodwill). No
Intangible Assets	Intangible Assets Intangible assets are stated at cost of acquisition less accumulated amortization and impairment loss, if any. Cost of acquisition includes the purchase price and any cost directly attributable to bringing the asset to its working condition for the intended use. The Company amortizes its finite-lived intangible assets on a straight-line basis over the estimated useful life of the respective assets which is generally the life of the related patents or licenses, seven years for customer relationships and five years for assembled workforces. See Note 5 for more information on intangible assets.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets, including certain identifiable intangibles held and to be used by the Company, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows and the estimated liquidation value of such long-lived assets and provides for impairment if such undiscounted cash flows are insufficient to recover the carrying amount of the long-lived assets. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value. Fair values are determined based on quoted market values, undiscounted cash flows or internal and external appraisals, as applicable. Assets to be disposed of are carried at the lower of carrying value or estimated fair value less cost to sell. No
Investments in Equity Securities	Investments in Equity Securities The Company’s equity investments consist of nonmarketable equity securities in privately held companies without readily determinable fair values. Unless accounted for under the equity method of accounting, the investments are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment in the same issuer. The Company applies the equity method of accounting to investments when it has significant influence, but not controlling interest, in the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. As discussed further in Note 6 as of September 30, 2024, the Company had one investment that is recorded applying the equity method of accounting. The Company’s proportionate share of the net income (loss) resulting from these investments is reported under the line item captioned “Share of losses from equity method investment” in the Company’s Consolidated Statements of Operations. The Company’s equity method investment is adjusted each period for the Company’s share of the investee’s income or loss and dividend paid, if any. The Company classifies distributions received from its equity method investment using the cumulative earnings approach in the Company’s Consolidated Statements of Cash Flows. The Company has reviewed the carrying value of its investments and has determined there was no impairment or observable price changes as of or for the three and nine months ended September 30, 2024 and 2023.
Fair Value Measurement	Fair Value Measurement As defined in ASC Topic 820, Fair Value Measurement (“ASC 820”), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). This fair value measurement framework applies at both the initial and subsequent measurement. The three levels of the fair value hierarchy defined by ASC 820 are as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities. Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include nonexchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars. Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value. The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses, other than acquisition-related expenses, approximate fair value because of the short-term nature of these instruments. The fair value of acquisition-related accrued expenses is categorized as Level 2 of the fair value hierarchy. The value of these instruments has been estimated using discounted cash flow analysis based on the Company’s incremental borrowing rate. The carrying value of the Company’s CRG Term Loan (defined below), which has a fixed interest rate approximates fair value based on instruments with similar terms (Level 2 inputs). The carrying value of the Company’s Cadence Term Loan (defined below), which had variable interest rates determined each month, approximates fair value based on instruments with similar terms (Level 2 inputs). The fair value of the contingent earnout consideration and the acquisition date fair value of goodwill and intangibles related to the acquisitions discussed in Notes 3 and 5 are based on Level 3 inputs. Liabilities for contingent consideration for the Precision Healing merger, acquisition of Scendia and Applied Asset Purchase (defined below) (see Note 3 for more information) are measured at fair value each reporting period, with the acquisition-date fair value included as part of the consideration transferred. The contingent consideration for the Scendia acquisition was settled as of September 30, 2024, and the final earnout payment of approximately $1.1 million was paid in cash in October 2024. Subsequent changes in fair value for the Precision Healing merger are reported under the line item captioned “Change in fair value of earnout liabilities” in the Company’s Consolidated Statements of Operations. Due to the Applied Asset Purchase being accounted for as an asset acquisition and given that the transaction did not include contingent shares, subsequent revaluations of contingent consideration for the Applied Asset Purchase results in an adjustment to the contingent consideration liability and the intellectual property intangible asset with a cumulative catch-up amortization adjustment. The current year change in fair value of earnout liability below is as a result of a net increase in the estimated fair value of the earnout liability established at the time of the Company’s Precision Healing merger. The current year revaluation of earnout liability below is a result of an increase in the estimated value of the earnout liability established at the time of the Applied Asset Purchase. The following table sets forth a summary of the changes in fair value for the Level 3 contingent earnout considerations. SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION Balance at December 31, 2023 $ 3,823,001 Change in fair value of earnout liabilities 67,549 Revaluation of earnout liability 22,000 Balance at September 30, 2024 $ 3,912,550
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method, whereby deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all the deferred tax asset will not be realized.
Share-based Compensation	Share-based Compensation The Company accounts for share-based compensation to employees and nonemployees in accordance with ASC Topic 718, Compensation – Stock Compensation. Share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as expense over the stipulated vesting period, if any. The Company estimates the fair value of share-based payments using the Black-Scholes option-pricing model for common stock options and warrants, and the closing price of the Company’s common stock for grants of common stock, including restricted stock awards.
Research and Development Costs	Research and Development Costs Research and development (“R&D”) expenses consist of personnel-related expenses, including salaries, share-based compensation and benefits for all personnel directly engaged in R&D activities, contracted services, materials, prototype expenses and allocated overhead, which is comprised of compensation and benefits, lease expense and other facilities-related costs. R&D expenses include costs related to enhancements to the Company’s currently available products and additional investments in the product and platform development pipeline. The Company expenses R&D costs as incurred.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326). This update amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The Company adopted the new guidance effective January 1, 2023. The adoption did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2023, FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires disclosure of incremental segment information on an annual and interim basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company is currently evaluating the effect of this pronouncement on its disclosures. In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which expands the disclosure required for income taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE	The following table summarizes the shares of common stock that were potentially issuable but were excluded from the computation of diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 as such shares would have had an anti-dilutive effect: SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE 2024 2023 As of September 30, 2024 2023 Stock options (a) 31,013 95,873 Warrants (b) 16,725 16,725 Unvested restricted stock 224,392 159,557 Anti-dilutive securities 224,392 159,557 (a) Shares underlying stock options assumed pursuant to the merger agreement with Precision Healing, Inc. (“Precision Healing”) in April 2022. (b) Shares underlying warrants assumed pursuant to the merger agreement with Precision Healing in April 2022.
SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES	Revenue streams from product sales and royalties are summarized below for the three and nine months ended September 30, 2024 and 2023. SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES 2024 2023 2024 2023 Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Soft tissue repair products $ 18,863,335 $ 13,634,316 $ 52,586,945 $ 39,756,539 Bone fusion products 2,808,264 2,340,382 7,779,209 7,392,740 Royalty revenue - 50,250 906 150,750 Total Net Revenue $ 21,671,599 $ 16,024,948 $ 60,367,060 $ 47,300,029
SCHEDULE OF PROPERTY AND EQUIPMENT	SCHEDULE OF PROPERTY AND EQUIPMENT Useful September 30, December 31, Life 2024 2023 Computers 3 5 $ 235,388 $ 194,788 Office equipment 3 7 216,491 201,785 Furniture and fixtures 5 10 346,508 304,338 Leasehold improvements 2 5 170,370 134,170 Internal use software 5 1,618,999 1,618,999 Property and equipment, gross 2,587,756 2,454,080 Less accumulated depreciation (1,591,986 ) (1,196,124 ) Property and equipment, net $ 995,770 $ 1,257,956
SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION	SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION Balance at December 31, 2023 $ 3,823,001 Change in fair value of earnout liabilities 67,549 Revaluation of earnout liability 22,000 Balance at September 30, 2024 $ 3,912,550

APPLIED ASSET PURCHASE (Tables)

APPLIED ASSET PURCHASE (Tables) - Applied Asset Purchase Agreement [Member]	9 Months Ended
	Sep. 30, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
SCHEDULE OF ASSET PURCHASE CONSIDERATIONS	The total purchase consideration for the Applied Asset Purchase as determined by the Company was as follows: SCHEDULE OF ASSET PURCHASE CONSIDERATIONS Consideration Equity Shares Dollar Value Cash Closing Consideration $ 9,750,000 Fair value of Stock Closing Consideration 73,809 3,089,645 Fair value of Installment Payments 2,040,808 Cash paid for inventory 30,007 Fair value of Petito Services Agreement defined payments 825,834 Fair value of Petito Services Agreement contingent consideration 893,000 Direct transaction costs 162,743 Total purchase consideration $ 16,792,037
SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED	SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED Description Amount Inventory $ 30,007 Equipment 33,062 Intellectual property 16,728,968 Net assets acquired $ 16,792,037

GOODWILL AND INTANGIBLES, NET (

GOODWILL AND INTANGIBLES, NET (Tables)	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF CHANGES IN CARRYING AMOUNT OF GOODWILL	The changes in the carrying amount of the Company’s goodwill were as follows: SCHEDULE OF CHANGES IN CARRYING AMOUNT OF GOODWILL Total Balance as of December 31, 2022 $ 3,601,781 Acquisitions - Balance as of December 31, 2023 3,601,781 Balance 3,601,781 Acquisitions - Balance as of September 30, 2024 $ 3,601,781 Balance $ 3,601,781
SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS	The carrying values of the Company’s intangible assets were as follows for the periods presented: SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS September 30, 2024 December 31, 2023 Accumulated Accumulated Cost Amortization Net Cost Amortization Net Amortizable Intangible Assets: Patents and Other IP $ 38,592,549 $ (4,934,785 ) $ 33,657,764 $ 38,570,549 $ (3,181,186 ) $ 35,389,363 Customer relationships and other 7,947,332 (2,737,675 ) 5,209,657 7,947,332 (1,861,887 ) 6,085,445 Product Licenses 4,793,879 (1,632,158 ) 3,161,721 4,793,879 (1,342,626 ) 3,451,253 Total $ 51,333,760 $ (9,304,618 ) $ 42,029,142 $ 51,311,760 $ (6,385,699 ) $ 44,926,061
SCHEDULE OF FUTURE AMORTIZATION EXPENSE	SCHEDULE OF FUTURE AMORTIZATION EXPENSE Remainder of 2024 $ 972,818 2025 3,891,270 2026 3,874,015 2027 3,760,162 2028 3,726,921 2029 3,726,921 Thereafter 22,077,035 Total $ 42,029,142

INVESTMENTS IN EQUITY SECURIT_2

INVESTMENTS IN EQUITY SECURITIES (Tables)	9 Months Ended
	Sep. 30, 2024
Schedule of Investments [Abstract]
SCHEDULE OF INVESTMENTS	The following table summarizes the Company’s investments for the periods presented: SCHEDULE OF INVESTMENTS September 30, 2024 December 31, 2023 Carrying Amount Economic Interest Carrying Amount Economic Interest Equity Method Investment ChemoMouthpiece, LLC $ 5,237,134 6.64 % $ - - % Cost Method Investments Direct Dermatology, Inc. $ 1,000,000 $ 1,000,000 Pixalere Healthcare Inc. 2,084,278 2,084,278 Total Cost Method Investments $ 3,084,278 $ 3,084,278 Total Investments $ 8,321,412 $ 3,084,278
SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT	The following table summarizes the Company’s share of losses from equity method investment reflected in the Company’s Consolidated Statements of Operations for the periods presented: SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT 2024 2023 2024 2023 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Investment ChemoMouthpiece, LLC $ (31,448 ) $ - $ (31,448 ) $ - Total $ (31,448 ) $ - $ (31,448 ) $ - Loss from equity method investment $ (31,448 ) $ - $ (31,448 ) $ -

OPERATING LEASES (Tables)

OPERATING LEASES (Tables)	9 Months Ended
	Sep. 30, 2024
Operating Leases
SCHEDULE OF OPERATING LEASE LIABILITY	Maturity of Operating Lease Liabilities SCHEDULE OF OPERATING LEASE LIABILITY September 30, Remainder of 2024 $ 142,525 2025 532,053 2026 379,529 2027 297,947 2028 295,689 2029 300,158 Thereafter 303,892 Total lease payments 2,251,793 Less imputed interest (405,500 ) Present Value of Lease Liabilities $ 1,846,293 Operating lease liabilities – current $ 439,129 Operating lease liabilities – long-term $ 1,407,164

DEBT AND CREDIT FACILITIES (Tab

DEBT AND CREDIT FACILITIES (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
SCHEDULE OF LONG-TERM DEBT	The table below presents the components of the Company’s outstanding debt for the periods presented: SCHEDULE OF LONG-TERM DEBT September 30, December 31, CRG Term Loan $ 30,500,000 $ - Paid-in-kind interest 424,067 - Back-end fee 219,689 - Cadence Term Loan - 9,750,000 Debt 31,143,756 9,750,000 Less: unamortized debt issuance costs (1,067,041 ) (56,520 ) Debt, net of debt issuance costs 30,076,715 9,693,480 Less: Current portion of debt - 580,357 Long-term debt, net of current portion $ 30,076,715 $ 9,113,123
SCHEDULE OF MATURITIES OUTSTANDING	The table below presents the aggregate maturities of the Company’s outstanding debt as of September 30, 2024: SCHEDULE OF MATURITIES OUTSTANDING Year Total Remainder of 2024 $ - 2025 - 2026 - 2027 - 2028 - Thereafter 31,143,756 Total debt $ 31,143,756

SHAREHOLDERS_ EQUITY (Tables)

SHAREHOLDERS’ EQUITY (Tables)	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
SUMMARY OF RESTRICTED STOCK ACTIVITY	Below is a summary of restricted stock activity for the nine months ended September 30, 2024: SUMMARY OF RESTRICTED STOCK ACTIVITY For the Nine Months Ended September 30, 2024 Shares Weighted Average Grant Date Fair Value Nonvested at beginning of period 144,211 $ 34.07 Granted 190,240 35.03 Vested (84,407 ) 33.26 Forfeited (25,652 ) 35.02 Nonvested at September 30, 2024 224,392 $ 35.08
SCHEDULE OF STOCK OPTION ACTIVITY	A summary of the status of outstanding stock options at September 30, 2024 and changes during the nine months then ended is presented below: SCHEDULE OF STOCK OPTION ACTIVITY For the Nine Months Ended September 30, 2024 Weighted Average Weighted Average Aggregate Exercise Remaining Intrinsic Options Price Contract Life Value Outstanding at beginning of period 93,892 $ 10.22 Granted or assumed - - Exercised (62,879 ) 10.05 Forfeited - - Expired - - Outstanding at September 30, 2024 31,013 $ 10.57 6.1 $ 547,530.6 Exercisable at September 30, 2024 31,013 $ 10.57 6.1 $ 547,530.6
SCHEDULE OF WARRANTS TO PURCHASE COMMON STOCK	A summary of the status of outstanding warrants to purchase common stock at September 30, 2024 and changes during the nine months then ended is presented below: SCHEDULE OF WARRANTS TO PURCHASE COMMON STOCK For the Nine Months Ended September 30, 2024 Weighted Average Weighted Average Exercise Remaining Warrants Price Contract Life Outstanding at beginning of period 16,725 $ 10.80 Granted or assumed - - Exercised - - Forfeited - - Expired - - Outstanding at September 30, 2024 16,725 $ 10.80 6.0 Exercisable at September 30, 2024 16,725 $ 10.80 6.0

SEGMENT REPORTING (Tables)

SEGMENT REPORTING (Tables)	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
SCHEDULE OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS	The following tables reflect results of operations, Segment EBITDA, segmented assets, and expenditures for long-lived assets for the Company’s reportable segments for the periods indicated below: SCHEDULE OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS Sanara Surgical THP Total Sanara Surgical THP Total Three Months Ended September 30, 2024 2023 Sanara Surgical THP Total Sanara Surgical THP Total Net revenue $ 21,671,599 $ - $ 21,671,599 $ 16,024,948 $ - $ 16,024,948 Gross profit 19,679,612 - 19,679,612 14,273,599 - 14,273,599 Selling, general and administrative expenses 17,420,346 1,572,909 18,993,255 13,460,404 417,475 13,877,879 Research and development 783,840 575,690 1,359,530 225,886 760,568 986,454 Depreciation and amortization 696,888 406,966 1,103,854 590,563 407,111 997,674 Interest expense 927,577 - 927,577 188,294 - 188,294 Net income (loss) (180,488 ) (2,702,564 ) (2,883,052 ) 567,235 (1,662,184 ) (1,094,949 ) Segment EBITDA 2,563,521 (1,721,560 ) 841,961 1,400,916 (1,134,124 ) 266,792 Segment assets (at period end) (1) $ 67,037,973 $ 21,507,503 $ 88,545,476 $ 45,715,495 $ 28,155,654 $ 73,871,149 Expenditures for long-lived assets $ 9,096 $ - $ 9,096 $ 170,320 $ - $ 170,320 Sanara Surgical THP Total Sanara Surgical THP Total Nine Months Ended September 30, 2024 2023 Sanara Surgical THP Total Sanara Surgical THP Total Net revenue $ 60,367,060 $ - $ 60,367,060 $ 47,297,299 $ 2,730 $ 47,300,029 Gross profit (loss) 54,476,341 - 54,476,341 41,241,740 (6,235 ) 41,235,505 Selling, general and administrative expenses 51,453,311 2,689,811 54,143,122 39,229,030 1,429,394 40,658,424 Research and development 1,945,263 1,346,216 3,291,479 669,849 2,811,057 3,480,906 Depreciation and amortization 2,093,797 1,220,984 3,314,781 1,359,180 1,221,063 2,580,243 Interest expense 1,839,259 - 1,839,259 188,300 - 188,300 Net income (loss) (2,872,286 ) (5,339,011 ) (8,211,297 ) 1,181,296 (5,358,754 ) (4,177,458 ) Segment EBITDA 5,095,670 (3,350,104 ) 1,745,566 3,766,196 (4,087,858 ) (321,662 ) Segment assets (at period end) (1) $ 67,037,973 $ 21,507,503 $ 88,545,476 $ 45,715,495 $ 28,155,654 $ 73,871,149 Expenditures for long-lived assets $ 133,676 $ - $ 133,676 $ 210,970 $ - $ 210,970 (1) - Segment assets for 2023 represent assets as of December 31, 2023.
SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS	The following tables provide a reconciliation of net income (loss) to Segment EBITDA for the Company’s reportable segments for the periods indicated below: SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS Sanara Surgical THP Total Sanara Surgical THP Total Three Months Ended September 30, 2024 2023 Sanara Surgical THP Total Sanara Surgical THP Total Net Income (Loss) $ (180,488 ) $ (2,702,564 ) $ (2,883,052 ) $ 567,235 $ (1,662,184 ) $ (1,094,949 ) Adjustments: Interest expense 927,577 - 927,577 188,294 - 188,294 Depreciation and amortization 696,888 406,966 1,103,854 590,563 407,111 997,674 Noncash share-based compensation 1,003,599 21,831 1,025,430 813,606 43,920 857,526 Change in fair value of earnout liabilities - 147,000 147,000 (758,783 ) 77,030 (681,753 ) Share of losses from equity method investment 31,448 - 31,448 - - - Executive separation costs 59,685 - 59,685 - - - Acquisition costs 24,812 405,207 430,019 - - - Segment EBITDA $ 2,563,521 $ (1,721,560 ) $ 841,961 $ 1,400,916 $ (1,134,124 ) $ 266,792 Sanara Surgical THP Total Sanara Surgical THP Total Nine Months Ended September 30, 2024 2023 Sanara Surgical THP Total Sanara Surgical THP Total Net Income (Loss) $ (2,872,286 ) $ (5,339,011 ) $ (8,211,297 ) $ 1,181,296 $ (5,358,754 ) $ (4,177,458 ) Adjustments: Interest expense 1,839,259 - 1,839,259 188,300 - 188,300 Depreciation and amortization 2,093,797 1,220,984 3,314,781 1,359,180 1,221,063 2,580,243 Noncash share-based compensation 2,803,536 108,031 2,911,567 2,423,335 158,828 2,582,163 Change in fair value of earnout liabilities (14,451 ) 82,000 67,549 (1,385,914 ) (108,996 ) (1,494,910 ) Share of losses from equity method investment 31,448 - 31,448 - - - Executive separation costs (1) 964,466 - 964,466 - - - Acquisition costs 249,901 577,892 827,793 - - - Segment EBITDA $ 5,095,670 $ (3,350,104 ) $ 1,745,566 $ 3,766,196 $ (4,087,858 ) $ (321,662 ) (1) - Includes $ 328,795

NATURE OF BUSINESS AND BACKGR_2

NATURE OF BUSINESS AND BACKGROUND (Details Narrative) - Integer	6 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segment		1
Number of reportable segment	2	1

SCHEDULE OF COMPUTATION OF DILU

SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE (Details) - shares		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	[1]	31,013	95,873
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	[2]	16,725	16,725
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		224,392	159,557
[1]Shares underlying stock options assumed pursuant to the merger agreement with Precision Healing, Inc. (“Precision Healing”) in April 2022.[2]Shares underlying warrants assumed pursuant to the merger agreement with Precision Healing in April 2022.

SCHEDULE OF REVENUE FROM PRODUC

SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Product Information [Line Items]
Total Net Revenue	$ 21,671,599	$ 16,024,948	$ 60,367,060	$ 47,300,029
Soft Tissue Repair Products [Member]
Product Information [Line Items]
Total Net Revenue	18,863,335	13,634,316	52,586,945	39,756,539
Bone Fusion Products [Member]
Product Information [Line Items]
Total Net Revenue	2,808,264	2,340,382	7,779,209	7,392,740
Royalty [Member]
Product Information [Line Items]
Total Net Revenue		$ 50,250	$ 906	$ 150,750

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,587,756	$ 2,454,080
Less accumulated depreciation	(1,591,986)	(1,196,124)
Property and equipment, net	$ 995,770	1,257,956
Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life	2 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life	10 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 235,388	194,788
Computer Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life	3 years
Computer Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life	5 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 216,491	201,785
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life	3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life	7 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 346,508	304,338
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life	10 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 170,370	134,170
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life	2 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life	5 years
Internal Use Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,618,999	$ 1,618,999
Useful life	5 years

SCHEDULE OF CHANGES IN FAIR VAL

SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION (Details)	9 Months Ended
	Sep. 30, 2024 USD ($)
Accounting Policies [Abstract]
Balance at December 31, 2023	$ 3,823,001
Change in fair value of earnout liabilities	67,549
Revaluation of earnout liability	22,000
Balance at September 30, 2024	$ 3,912,550

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Credit loss expense	$ 75,000	$ 128,061	$ 230,930	$ 214,061
Allowance for credit losses	758,960		758,960		$ 528,030
Allowance for customer rebates and deductions	5,010		5,010		3,820
Inventory obsolescence expense	96,684	152,701	356,261	222,691
Allowance for obsolete and slow-moving inventory	466,276		466,276		$ 446,917
Depreciation expense	$ 129,592	116,596	$ 395,862	332,762
Software, estimated useful life	5 years		5 years
Impairment of goodwill	$ 0	0	$ 0	0
Impairment of long-lived assets	$ 0	$ 0	$ 0	$ 0
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	2 years		2 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years		10 years

SCHEDULE OF ASSET PURCHASE CONS

SCHEDULE OF ASSET PURCHASE CONSIDERATIONS (Details) - Applied Asset Purchase Agreement [Member]	Aug. 01, 2023 USD ($) shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash Closing Consideration	$ 9,750,000
Fair value of Stock Closing Consideration	$ 3,089,645
Equity Shares | shares	73,809
Fair value of Installment Payments	$ 2,040,808
Cash paid for inventory	30,007
Fair value of Petito Services Agreement defined payments	825,834
Fair value of Petito Services Agreement contingent consideration	893,000
Direct transaction costs	162,743
Total purchase consideration	$ 16,792,037

SCHEDULE OF PURCHASE CONSIDERAT

SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED (Details) - Applied Asset Purchase Agreement [Member]	Sep. 30, 2024 USD ($)
Business Acquisition [Line Items]
Inventory	$ 30,007
Equipment	33,062
Intellectual property	16,728,968
Net assets acquired	$ 16,792,037

APPLIED ASSET PURCHASE (Details

APPLIED ASSET PURCHASE (Details Narrative) - Applied Asset Purchase Agreement [Member] - USD ($)		1 Months Ended
	Aug. 01, 2023	Aug. 31, 2024
Business Acquisition, Contingent Consideration [Line Items]
Assets purchase price	$ 15,250,000
Cash consideration paid	$ 9,750,000
Shares issued as consideration	73,809
Value of shares issued as consideration	$ 3,089,645
Installment payable	2,500,000
Payment of installment		$ 625,000
Earnout payable	$ 10,000,000
Purchase agreement description	As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the term of the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of certain products the Owner develops or co-develops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for the first $50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half percent (2.5%) on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0 million, (iv) $500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0 million in cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments described in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.
Cash Closing Consideration [Member]
Business Acquisition, Contingent Consideration [Line Items]
Cash consideration paid	$ 9,750,000
Stock Closing Consideration [Member]
Business Acquisition, Contingent Consideration [Line Items]
Shares issued as consideration	73,809
Value of shares issued as consideration	$ 3,000,000

CONVERTIBLE LOAN RECEIVABLE (De

CONVERTIBLE LOAN RECEIVABLE (Details Narrative) - USD ($)	Oct. 01, 2024	Sep. 30, 2024	Jul. 31, 2024	Dec. 31, 2023
Financing Receivable, Modified [Line Items]
Other Receivables, Net, Current		$ 1,079,411
Convertible Debt [Member]
Financing Receivable, Modified [Line Items]
Accounts and Financing Receivable, after Allowance for Credit Loss, Current			$ 1,079,391
Extended maturity date			Oct. 01, 2024
Other Receivables, Net, Current		$ 1,079,391
Convertible Debt [Member] | Subsequent Event [Member]
Financing Receivable, Modified [Line Items]
Loans Receivable, Basis Spread on Variable Rate	8%
Convertible Debt [Member] | Extended Maturity [Member]
Financing Receivable, Modified [Line Items]
Extended maturity date			Dec. 01, 2024

SCHEDULE OF CHANGES IN CARRYING

SCHEDULE OF CHANGES IN CARRYING AMOUNT OF GOODWILL (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Balance	$ 3,601,781	$ 3,601,781
Acquisitions
Balance	$ 3,601,781	$ 3,601,781

SCHEDULE OF CARRYING VALUE OF I

SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Net	$ 42,029,142	$ 44,926,061
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	38,592,549	38,570,549
Accumulated amortization	(4,934,785)	(3,181,186)
Net	33,657,764	35,389,363
Customer Relationships and Other [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	7,947,332	7,947,332
Accumulated amortization	(2,737,675)	(1,861,887)
Net	5,209,657	6,085,445
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	4,793,879	4,793,879
Accumulated amortization	(1,632,158)	(1,342,626)
Net	3,161,721	3,451,253
Amortizable Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	51,333,760	51,311,760
Accumulated amortization	(9,304,618)	(6,385,699)
Net	$ 42,029,142	$ 44,926,061

SCHEDULE OF FUTURE AMORTIZATION

SCHEDULE OF FUTURE AMORTIZATION EXPENSE (Details)	Sep. 30, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2024	$ 972,818
2025	3,891,270
2026	3,874,015
2027	3,760,162
2028	3,726,921
2029	3,726,921
Thereafter	22,077,035
Total	$ 42,029,142

GOODWILL AND INTANGIBLES, NET_2

GOODWILL AND INTANGIBLES, NET (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Weighted-average amortization period			14 years 6 months
Amortization of intangible assets	$ 974,262	$ 881,079	$ 2,918,919	$ 2,247,482

SCHEDULE OF INVESTMENTS (Detail

SCHEDULE OF INVESTMENTS (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Cost method investment	$ 3,084,278	$ 3,084,278
Total Investments	8,321,412	3,084,278
ChemoMouthpiece, LLC [Member]
Equity method investment	$ 5,237,134
Economic interest	6.64%
Direct Dermatology Inc. [Member]
Cost method investment	$ 1,000,000	$ 1,000,000
Pixalere Healthcare Inc. [Member]
Cost method investment	$ 2,084,278	$ 2,084,278

SCHEDULE OF LOSS FROM EQUITY ME

SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Loss from equity method investment	$ (31,448)		$ (31,448)
ChemoMouthpiece, LLC [Member]
Loss from equity method investment	$ (31,448)		$ (31,448)

INVESTMENTS IN EQUITY SECURIT_3

INVESTMENTS IN EQUITY SECURITIES (Details Narrative) - USD ($)	1 Months Ended				3 Months Ended		12 Months Ended
	Sep. 30, 2024	Mar. 31, 2022	Jun. 30, 2021	Jul. 31, 2020	Sep. 30, 2024	Mar. 31, 2023	Dec. 31, 2021	Dec. 31, 2023
Long term investments	$ 8,321,412				$ 8,321,412			$ 3,084,278
Purchase of shares, value					(75,000)	$ 1,033,761
Investments	$ 8,321,412				$ 8,321,412			$ 3,084,278
Direct Dermatology Inc. [Member]
Ownership interest	8.10%				8.10%
Pixalere Healthcare USA LLC [Member]
Ownership interest			27.30%
Ownership value			$ 93,879
ChemoMouthpiece, LLC [Member]
Ownership interest	6.64%				6.64%
Series B-2 Preferred Shares [Member] | Direct Dermatology Inc. [Member]
Ownership interest				2.90%
Direct Dermatology Inc. [Member] | Series B-2 Preferred Shares [Member]
Long term investments				$ 500,000
Number of shares purchased		3,571,429		7,142,857			3,571,430
Purchase of shares, value		$ 250,000					$ 250,000
Pixalere Healthcare Inc. [Member] | Class A Preferred Shares [Member]
Number of shares purchased			278,587
Investments			$ 2,084,278
Conversion rate			27.30%
ChemoMouthpiece, LLC [Member] | Common Units [Member]
Number of shares purchased	100,674.72
Purchase of shares, value	$ 5,000,000

SCHEDULE OF OPERATING LEASE LIA

SCHEDULE OF OPERATING LEASE LIABILITY (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Operating Leases
Remainder of 2024	$ 142,525
2025	532,053
2026	379,529
2027	297,947
2028	295,689
2029	300,158
Thereafter	303,892
Total lease payments	2,251,793
Less imputed interest	(405,500)
Present Value of Lease Liabilities	1,846,293
Operating lease liabilities – current	439,129	$ 361,185
Operating lease liabilities – long-term	$ 1,407,164	$ 1,737,445

OPERATING LEASES (Details Narra

OPERATING LEASES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Operating lease right of use assets	$ 1,688,963		$ 1,688,963		$ 1,995,204
Operating lease liability	1,846,293		1,846,293
Operating lease expense	$ 121,126	$ 110,693	416,394	$ 295,268
Operating lease payments			$ 362,491	$ 264,291
Weighted average remaining lease term	5 years 4 months 24 days		5 years 4 months 24 days
Weighted average discount rate	7.66%		7.66%
Office Space One [Member]
Property, Plant and Equipment [Line Items]
Remaining lease term	75 months		75 months
Office Space Two [Member]
Property, Plant and Equipment [Line Items]
Remaining lease term	11 months		11 months
Office Space Three [Member]
Property, Plant and Equipment [Line Items]
Remaining lease term	28 months		28 months

SCHEDULE OF LONG-TERM DEBT (Det

SCHEDULE OF LONG-TERM DEBT (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Short-Term Debt [Line Items]
Debt	$ 31,143,756	$ 9,750,000
Less: unamortized debt issuance costs	(1,067,041)	(56,520)
Debt, net of debt issuance costs	30,076,715	9,693,480
Less: Current portion of debt		580,357
Long-term debt, net of current portion	30,076,715	9,113,123
CRG Term Loan [Member]
Short-Term Debt [Line Items]
Debt	30,500,000
Paid-in-kind Interest [Member]
Short-Term Debt [Line Items]
Debt	424,067
Back-end Fee [Member]
Short-Term Debt [Line Items]
Debt	219,689
Cadence Term Loan [Member]
Short-Term Debt [Line Items]
Debt		$ 9,750,000

SCHEDULE OF MATURITIES OUTSTAND

SCHEDULE OF MATURITIES OUTSTANDING (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Remainder of 2024
2026
2027
2028
Thereafter	31,143,756
Total debt	$ 31,143,756	$ 9,750,000

DEBT AND CREDIT FACILITIES (Det

DEBT AND CREDIT FACILITIES (Details Narrative) - USD ($)			3 Months Ended		9 Months Ended
	Sep. 04, 2024	Apr. 17, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Aug. 01, 2024	Dec. 31, 2023	Aug. 01, 2023
Short-Term Debt [Line Items]
Interest paid-in-kind					$ 424,067
Interest expense related to back-end fee			$ 927,577	$ 188,294	1,839,259	188,300
Minimum cash balance			3,000,000		3,000,000
Annual minimum revenue, year one					60,000,000
Annual minimum revenue, year two					75,000,000
Annual minimum revenue, year three					85,000,000
Annual minimum revenue, year four					95,000,000
Annual minimum revenue, year five					105,000,000
Unamortized debt issuance costs			1,067,041		1,067,041			$ 56,520
Amortization expense of debt issuance costs					150,219	$ 2,055
CRG Term Loan [Member]
Short-Term Debt [Line Items]
Debt issuance costs			1,160,740		1,160,740
Increase in debt issuance costs			273,487
Cadence Term Loan [Member]
Short-Term Debt [Line Items]
Write-off of debt issuance costs					56,520
CRG Term Loan Agreement [Member]
Short-Term Debt [Line Items]
Secured term loan		$ 55,000,000
Loans borrowed	$ 15,500,000	15,000,000
Remaining amount available for borrowing		$ 40,000,000
Borrowing capacity description		each such borrowing must be at least $5.0 million or a multiple of $5.0 million and occur between the Closing Date and June 30, 2025,
Proceeds from loans used for investment	$ 5,000,000
Debt maturity date	Mar. 30, 2029
Interest rate per annum		13.25%
Incremental increase during an event of default		4%
Cash paid percentage		8%
Paid-in-kind and aggregate principal loan amount, percentage		5.25%
Debt upfront fee percentage		1.50%
Debt instrument back-end fee percentage		7%
Interest paid			399,532		646,199
Interest paid-in-kind			262,193		424,068
Debt instrument rate description		(i) if prepayment occurs on or prior to the date that is one year following the applicable borrowing (the “Borrowing Date”), an amount equal to 10.0% of the aggregate outstanding principal amount of the CRG Term Loan being prepaid and (ii) if prepayment occurs one year after the applicable Borrowing Date and on or prior to two years following the applicable Borrowing Date, an amount equal to 5.0% of the aggregate outstanding principal amount of the CRG Term Loan being prepaid.
CRG Term Loan Agreement [Member] | Back-end Fee [Member]
Short-Term Debt [Line Items]
Interest expense related to back-end fee			$ 167,189		219,689
Cadence Term Loan Agreement [Member]
Short-Term Debt [Line Items]
Principal amount									$ 12,000,000
Loan percentage used for acquisition									100%
Loan bank advance									$ 9,750,000
Bank, interest rate							3%
Interest rate on advances								8.30%
Interest expense					$ 53,438

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Jan. 01, 2024

Dec. 20, 2023

Aug. 01, 2023

Aug. 27, 2018

Oct. 31, 2024

Aug. 31, 2023

Jul. 31, 2022

Apr. 30, 2022

May 31, 2020

Oct. 31, 2019

Jul. 31, 2019

Sep. 30, 2024

Sep. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Dec. 31, 2025

Apr. 04, 2022

Apr. 30, 2020

Loss Contingencies [Line Items]

Payment in cash

$ 3,089,645

Options to acquire shares

Cost of Sales [Member]

Loss Contingencies [Line Items]

Payment for additional royalties

9,209

$ 1,060,035

Sub License Agreement [Member]

Loss Contingencies [Line Items]

License agreement and royalties description

In August 2018, the Company entered an exclusive, world-wide sublicense agreement with CGI Cellerate RX to distribute certain hydrolyzed collagen products, including CellerateRX Surgical, into the surgical and wound care markets. Pursuant to the Sublicense Agreement, the Company paid royalties of 3-5% of annual collected net sales of these products. As amended in January 2021, the term of the sublicense was extended through May 2050, with automatic successive year-to-year renewal terms thereafter so long as the Company’s Net Sales (as defined in the Sublicense Agreement) each year are equal to or in excess of $1,000,000. If the Company’s Net Sales fall below $1,000,000 for any year after the expiration date, CGI Cellerate RX has the right to terminate the Sublicense Agreement upon written notice.

BIAKOS License Agreement [Member]

Loss Contingencies [Line Items]

Payment for additional royalties

$ 36,602

$ 32,499

113,907

$ 97,499

BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Minimum [Member]

Loss Contingencies [Line Items]

Royalty percentage

2%

Annual royalty

$ 146,410

BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Maximum [Member]

Loss Contingencies [Line Items]

Royalty percentage

4%

BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Maximum [Member] | Forecast [Member]

Loss Contingencies [Line Items]

Annual royalty

$ 150,000

BIAKOS Agreement [Member] | Maximum [Member]

Loss Contingencies [Line Items]

Payment for additional royalties

$ 1,000,000

ABF License Agreement [Member]

Loss Contingencies [Line Items]

Increase in royalty annual percentage

10%

ABF License Agreement [Member] | Minimum [Member]

Loss Contingencies [Line Items]

Payment for additional royalties

$ 50,000

Royalty percentage

2%

ABF License Agreement [Member] | Maximum [Member]

Loss Contingencies [Line Items]

Payment for additional royalties

$ 75,000

Royalty percentage

4%

ABF License Agreement [Member] | Maximum [Member] | Product and Service, Other [Member]

Loss Contingencies [Line Items]

Payment for additional royalties

$ 500,000

Debrider License Agreement [Member]

Loss Contingencies [Line Items]

Increase in royalty annual percentage

10%

Payment of cash

$ 1,000,000

Debrider License Agreement [Member] | Rochal [Member]

Loss Contingencies [Line Items]

Cash

$ 500,000

Debrider License Agreement [Member] | Minimum [Member]

Loss Contingencies [Line Items]

Royalty percentage

2%

Annual royalty

$ 100,000

Debrider License Agreement [Member] | Maximum [Member]

Loss Contingencies [Line Items]

Royalty percentage

4%

Annual royalty

$ 150,000

Payment for additional royalties

$ 1,000,000

Precision Healing Merger Agreement [Member]

Loss Contingencies [Line Items]

Cash consideration

$ 125,966

Payment in cash

$ 600,000

Share price

$ 27.13

$ 30.75

$ 27.13

Options to acquire shares

144,191

Weighted exercise price

$ 10.71

Contingent consideration payments receivable

$ 10,000,000

Precision Healing Merger Agreement [Member] | Warrant [Member]

Loss Contingencies [Line Items]

Warrants to purchase shares

4,424

Exercise price

$ 7.32

Expiration date

Apr. 22, 2031

Precision Healing Merger Agreement [Member] | Warrant One [Member]

Loss Contingencies [Line Items]

Warrants to purchase shares

12,301

Exercise price

$ 12.05

Expiration date

Aug. 10, 2030

Precision Healing Merger Agreement [Member] | Accredited Investors [Member]

Loss Contingencies [Line Items]

Issuance of shares

165,738

Scendia Purchase Agreement [Member]

Loss Contingencies [Line Items]

Cash

$ 1,600,000

Acquisition consideration transferred

$ 7,600,000

Issuance of common stock for purchase of assets

291,686

Number of shares withheld

94,798

Earnout consideration

$ 10,000,000

Number of shares issuable

486,145

Earnout payment

$ 693,000

Assets purchase price

$ 7,600,000

Scendia Purchase Agreement [Member] | Subsequent Event [Member]

Loss Contingencies [Line Items]

Earnout payment

$ 1,100,000

Applied Asset Purchase Agreement [Member]

Loss Contingencies [Line Items]

Cash consideration

$ 16,792,037

Contingent consideration payments receivable

$ 893,000

Issuance of common stock for purchase of assets

73,809

Assets purchase price

$ 15,250,000

Purchase agreement description

As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the term of the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of certain products the Owner develops or co-develops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for the first $50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half percent (2.5%) on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0 million, (iv) $500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0 million in cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments described in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.

Services Agreement [Member]

Loss Contingencies [Line Items]

Purchase agreement description

As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the term of the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of certain products the Owner develops or codevelops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for the first $50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half percent (2.5%) on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0 million, (iv) $500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0 million in cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments described in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.

License Agreement [Member]

Loss Contingencies [Line Items]

Payment for additional royalties

$ 50,000

Outstanding units percentage

10%

License Agreement [Member] | Royalty Agreement Terms [Member]

Loss Contingencies [Line Items]

Payment for additional royalties

$ 100,000

License Agreement [Member] | Minimum [Member]

Loss Contingencies [Line Items]

Royalty expense percentage

1.50%

License Agreement [Member] | Maximum [Member]

Loss Contingencies [Line Items]

Royalty expense percentage

3%

SUMMARY OF RESTRICTED STOCK ACT

SUMMARY OF RESTRICTED STOCK ACTIVITY (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Non-vested shares, beginning | shares	144,211
Weighted average grant date fair value, beginning | $ / shares	$ 34.07
Granted | shares	190,240
Weighted average grant date fair value, granted | $ / shares	$ 35.03
Vested | shares	(84,407)
Weighted average grant date fair value, vested | $ / shares	$ 33.26
Forfeited | shares	(25,652)
Weighted average grant date fair value, forfeited | $ / shares	$ 35.02
Non-vested shares, ending | shares	224,392
Weighted average grant date fair value, ending | $ / shares	$ 35.08

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details)	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Equity [Abstract]
Options outstanding, beginning | shares	93,892
Weighted average exercise price outstanding, beginning | $ / shares	$ 10.22
Options, Granted or assumed | shares
Weighted average exercise price, Granted or assumed | $ / shares
Options, Exercised | shares	(62,879)
Weighted average exercise price, Exercised | $ / shares	$ 10.05
Options, Forfeited | shares
Weighted average exercise price, Forfeited | $ / shares
Options, Expired | shares
Weighted average exercise price, Expired | $ / shares
Options outstanding, ending | shares	31,013
Weighted average exercise price outstanding, ending | $ / shares	$ 10.57
Weighted average remaining contract life outstanding	6 years 1 month 6 days
Aggregate intrinsic value, ending | $	$ 547,530.6
Options exercisable, ending | shares	31,013
Weighted average exercise price exercisable, ending | $ / shares	$ 10.57
Weighted average remaining contract life exercisable	6 years 1 month 6 days
Aggregate intrinsic value, exercisable | $	$ 547,530.6

SCHEDULE OF WARRANTS TO PURCHAS

SCHEDULE OF WARRANTS TO PURCHASE COMMON STOCK (Details)	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Equity [Abstract]
Number of warrants outstanding, beginning | shares	16,725
Weighted average exercise price outstanding, beginning | $ / shares	$ 10.80
Number of warrants, granted | shares
Weighted average exercise price, granted | $ / shares
Number of warrants, exercised | shares
Weighted average exercise price, exercised | $ / shares
Number of warrants, forfeited | shares
Weighted average exercise price, forfeited | $ / shares
Number of warrants, expired | shares
Weighted average exercise price, expired | $ / shares
Number of warrants outstanding, ending | shares	16,725
Weighted average exercise price outstanding, ending | $ / shares	$ 10.80
Weighted average remaining contract life outstanding	6 years
Number of warrants exercisable, ending | shares	16,725
Weighted average exercise price, exercisable, ending | $ / shares	$ 10.80
Weighted average remaining contract life exercisable, ending	6 years

SHAREHOLDERS_ EQUITY (Details N

SHAREHOLDERS’ EQUITY (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2024

Aug. 01, 2023

Oct. 31, 2024

Aug. 31, 2023

Feb. 28, 2023

Jul. 31, 2022

Apr. 30, 2022

Sep. 30, 2024

Sep. 30, 2023

Mar. 31, 2023

Sep. 30, 2024

Sep. 30, 2023

Dec. 31, 2023

Jun. 12, 2024

Apr. 04, 2022

Apr. 30, 2020

Accumulated Other Comprehensive Income (Loss) [Line Items]

Payment in cash

$ 3,089,645

Options to acquire shares

Number of shares issued, value

$ (75,000)

$ 1,033,761

Share-based compensation expense

$ 3,240,362

$ 2,582,163

Restricted Stock Units (RSUs) [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share-based compensation expense

1,025,430

$ 857,526

3,240,361

$ 2,582,163

Unrecognized share-based compensation expense

$ 5,403,255

5,403,255

$ 5,403,255

Unrecognized share-based compensation expense period for recognition

8 months 12 days

Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Accredited investors shares

73,809

Payment in cash

$ 74

Sale of stock

26,143

Number of shares issued, value

$ 26

Precision Healing Merger Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Cash consideration

$ 125,966

Payment in cash

$ 600,000

Share price

$ 27.13

$ 30.75

$ 27.13

Options to acquire shares

144,191

Weighted exercise price

$ 10.71

Payment of contingent consideration

$ 10,000,000

Precision Healing Merger Agreement [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase shares

4,424

Exercise price

$ 7.32

Expiration date

Apr. 22, 2031

Precision Healing Merger Agreement [Member] | Warrant One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase shares

12,301

Exercise price

$ 12.05

Expiration date

Aug. 10, 2030

Precision Healing Merger Agreement [Member] | Accredited Investors [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Accredited investors shares

165,738

Scendia Purchase Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Purchase price

$ 7,600,000

Cash

$ 1,600,000

Equity Shares

291,686

Number of shares withheld

94,798

Cash consideration

$ 10,000,000

Number of shares

486,145

Earnout payment

$ 693,000

Scendia Purchase Agreement [Member] | Subsequent Event [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Earnout payment

$ 1,100,000

Sales Agreement [Member] | Cantor Fitzgerald & Co [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Percentage of commissions payable to sales agent

3%

Sales Agreement [Member] | Cantor Fitzgerald & Co [Member] | Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Sale of stock, consideration received on transaction

$ 75,000,000

Sales Agreement [Member] | Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Sale of stock

26,143

Number of shares issued, value

$ 1,100,000

Net proceeds

$ 900,000

Applied Asset Purchase Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Cash consideration

$ 16,792,037

Payment of contingent consideration

893,000

Purchase price

$ 15,250,000

Equity Shares

73,809

2024 Omnibus Long-Term Incentive Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Maximum number of shares available for grant

1,000,000

Number of shares issued

745,085

Number of shares available for issuance

1,000,000

1,000,000

1,000,000

2024 Omnibus Long-Term Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Restricted stock awards granted and issued

164,588

Restricted stock awards granted and issued, fair value

$ 5,765,952

RELATED PARTIES (Details Narrat

RELATED PARTIES (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Jul. 31, 2021	Jan. 31, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Consulting Agreement [Member] | Ms Salamone [Member]
Related Party Transaction [Line Items]
Consulting fee	$ 177,697
CellerateRx Sublicense Agreement [Member]
Related Party Transaction [Line Items]
Net sale		$ 1,000,000
Services Agreement [Member]
Related Party Transaction [Line Items]
Cost and expenses related party			$ 49,829	$ 44,032	$ 163,101	$ 117,018

SCHEDULE OF OPERATIONS, ASSETS

SCHEDULE OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS (Details) - USD ($)		3 Months Ended						9 Months Ended
		Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Segment Reporting Information [Line Items]
Net revenue		$ 21,671,599			$ 16,024,948			$ 60,367,060	$ 47,300,029
Gross profit (loss)		19,679,612			14,273,599			54,476,341	41,235,505
Selling, general and administrative expenses		18,993,255			13,877,879			54,143,122	40,658,424
Research and development		1,359,530			986,454			3,291,479	3,480,906
Depreciation and amortization		1,103,854			997,674			3,314,781	2,580,243
Interest expense		927,577			188,294			1,839,259	188,300
Net income (loss)		(2,883,052)	$ (3,529,202)	$ (1,799,043)	(1,094,949)	$ (1,866,180)	$ (1,216,329)	(8,211,297)	(4,177,458)
Segment EBITDA		841,961			266,792			1,745,566	(321,662)
Segment assets (at period end)	[1]	88,545,476			73,871,149			88,545,476	73,871,149
Expenditures for long-lived assets		9,096			170,320			133,676	210,970
Sanara Surgical [Member]
Segment Reporting Information [Line Items]
Net revenue		21,671,599			16,024,948			60,367,060	47,297,299
Gross profit (loss)		19,679,612			14,273,599			54,476,341	41,241,740
Selling, general and administrative expenses		17,420,346			13,460,404			51,453,311	39,229,030
Research and development		783,840			225,886			1,945,263	669,849
Depreciation and amortization		696,888			590,563			2,093,797	1,359,180
Interest expense		927,577			188,294			1,839,259	188,300
Net income (loss)		(180,488)			567,235			(2,872,286)	1,181,296
Segment EBITDA		2,563,521			1,400,916			5,095,670	3,766,196
Segment assets (at period end)	[1]	67,037,973			45,715,495			67,037,973	45,715,495
Expenditures for long-lived assets		9,096			170,320			133,676	210,970
THP [Member]
Segment Reporting Information [Line Items]
Net revenue									2,730
Gross profit (loss)									(6,235)
Selling, general and administrative expenses		1,572,909			417,475			2,689,811	1,429,394
Research and development		575,690			760,568			1,346,216	2,811,057
Depreciation and amortization		406,966			407,111			1,220,984	1,221,063
Interest expense
Net income (loss)		(2,702,564)			(1,662,184)			(5,339,011)	(5,358,754)
Segment EBITDA		(1,721,560)			(1,134,124)			(3,350,104)	(4,087,858)
Segment assets (at period end)	[1]	21,507,503			28,155,654			21,507,503	28,155,654
Expenditures for long-lived assets
[1]- Segment assets for 2023 represent assets as of December 31, 2023.

SCHEDULE OF RECONCILIATION OF N

SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024		Sep. 30, 2023
Segment Reporting Information [Line Items]
Net Income (Loss)	$ (2,883,052)	$ (3,529,202)	$ (1,799,043)	$ (1,094,949)	$ (1,866,180)	$ (1,216,329)	$ (8,211,297)		$ (4,177,458)
Interest expense	927,577			188,294			1,839,259		188,300
Depreciation and amortization	1,103,854			997,674			3,314,781		2,580,243
Noncash share-based compensation	1,025,430			857,526			2,911,567		2,582,163
Change in fair value of earnout liabilities	147,000			(681,753)			67,549		(1,494,910)
Share of losses from equity method investment	31,448						31,448
Executive separation costs	59,685						964,466	[1]		[1]
Acquisition costs	430,019						827,793
Segment EBITDA	841,961			266,792			1,745,566		(321,662)
Sanara Surgical [Member]
Segment Reporting Information [Line Items]
Net Income (Loss)	(180,488)			567,235			(2,872,286)		1,181,296
Interest expense	927,577			188,294			1,839,259		188,300
Depreciation and amortization	696,888			590,563			2,093,797		1,359,180
Noncash share-based compensation	1,003,599			813,606			2,803,536		2,423,335
Change in fair value of earnout liabilities				(758,783)			(14,451)		(1,385,914)
Share of losses from equity method investment	31,448						31,448
Executive separation costs	59,685						964,466	[1]		[1]
Acquisition costs	24,812						249,901
Segment EBITDA	2,563,521			1,400,916			5,095,670		3,766,196
THP [Member]
Segment Reporting Information [Line Items]
Net Income (Loss)	(2,702,564)			(1,662,184)			(5,339,011)		(5,358,754)
Interest expense
Depreciation and amortization	406,966			407,111			1,220,984		1,221,063
Noncash share-based compensation	21,831			43,920			108,031		158,828
Change in fair value of earnout liabilities	147,000			77,030			82,000		(108,996)
Share of losses from equity method investment
Executive separation costs								[1]		[1]
Acquisition costs	405,207						577,892
Segment EBITDA	$ (1,721,560)			$ (1,134,124)			$ (3,350,104)		$ (4,087,858)
[1]- Includes $ 328,795

SCHEDULE OF RECONCILIATION OF_2

SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details) (Parenthetical)	9 Months Ended
	Sep. 30, 2024 USD ($)
Segment Reporting [Abstract]
Share based compensation related to executive separation costs	$ 328,795

SEGMENT REPORTING (Details Narr

SEGMENT REPORTING (Details Narrative) - Integer	6 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Segment Reporting [Abstract]
Number of operating segment		1
Number of reportable segment	2	1